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ABSTRACT
Nanomedicine is defined as the application of knowledge and tools of nanotechnology for
disease treatment, diagnosis, monitoring, delivery, and sensing. Rapid advances in polymer
chemistry and nanotechnology have led to an extensive development of polymeric-based
therapeutic systems for nanomedical applications. Compared to traditional molecular-based
therapies, polymers facilitate a higher level of versatility and functionality, such as simultaneous
imaging and delivery. In particular, amphiphilic diblock copolymers and their self-assemblies have
shown apparent success in nanomedicine owing to their ability to provide narrow molar mass
distributions and highly ordered nanoscale multimolecular aggregates, including micelles and
vesicles. However, engineering these polymeric materials to form nanoaggregates with the desired
size and morphology remains a challenge. Furthermore, conventional diblock copolymeric
nanoaggregates fail to provide expected in-vivo efficacy due to the insufficient mechanical stability
and adverse interactions with bloodstream components. Herein is presented a novel approach taken
to produce next-generation biomaterials polyesters (polylactides (PLA) and polycaprolactones
(PCL)) and polyamidoamine (PAMAM). Rather than using conventional block copolymeric
architectures, a linear dendritic architecture was developed. A feasible and robust synthetic
strategy was used to synthesize a library of amphiphilic linear dendritic block copolymers
(LDBCs) with well-controlled hydrophobic to hydrophilic weight ratios. Systems with
ii

hydrophobic weight ratios higher than 70% formed nanoparticles in aqueous media exhibiting
morphologies, hydrodynamic diameters, and surface properties suitable for enhanced permeability
retention effect (EPR) mediated therapeutic delivery. Aiming to apply these materials towards
theranostics, hydrophobic imaging and photothermal agents were successfully loaded and
trafficked into the endosomal and lysosomal compartments of human embryonic kidney (HEK)
cells and Schneider 2 (S2) cells without inducing significant cell death. Photothermally induced
cell death was observed, confirming the potential of these LDBCs as promising candidates in
nanomedicine. To enhance the stability and hydrophobic loading, the hydrophobic core-forming
polymer chains of the nanoparticle were crosslinked. Core-crosslinked LDBC nanoparticles
demonstrated increased stability and hydrophobic loading efficiencies relative to the noncrosslinked systems. Such insights provide a pathway toward nanomaterials with enhanced
stability, unique morphologies, and tunable properties deemed relevant in developing nextgeneration biomaterials.
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CHAPTER I: INTRODUCTION

1.1 NANOMEDICINE
Nanotechnology is a well-known and well-studied concept that has gained significant
attention in recent years. The general meaning of the prefix “nano” stands for “one-billionth”. As
an example, in the metric system, a nanometer means one-billionth of a meter. In the material
science perspective, the term “nanotechnology” is often used to represent the construction of
nanoscale materials with dimensions between 1 and 100 nm.1,2 However, the recent advances in
the fields of nanotechnology have expanded the scope of this definition. 3–5

Figure 1. Different fields of nanomedical research and applications.6

1

Nanomedicine is one of the emerging aspects of nanotechnology. According to the National
Institute of Health (NIH) definition: “nanomedicine” is the application of knowledge and tools of
nanotechnology to disease treatment and prevention, diagnosis, monitoring, delivery, and sensing.
6

The recent advances in the field of nanomedicine involve efficient delivery and targeting of

therapeutic, imaging, and diagnostic agents via functionalized nanoparticles (Fig. 1).

7,8

Nanomedicine has revolutionized the scope of material science, nanotechnology, and medicine
because it addresses the drawbacks of conventional therapeutics. 9–13
Aspects of therapeutic selectivity have limited conventional medicine.

In general,

circulation occurs and often demands higher dosages to reach the target site and provide expected
efficacy.

14–16

In addition, low solubility, low stability, and high hydrophobicity further reduce

their efficiency.

17–20

Chemotherapeutics are an excellent example to prove the need for an

improved method of delivery. Chemotherapeutic agents are often highly potent in in-vitro
applications, killing most cancer cells at picomolar to micromolar concentrations. However, they
generally fail to provide the expected therapeutic efficacy in-vivo due to inefficient accumulation
and low retention at the target site. Furthermore, significant amounts of these drugs are
accumulated in other fast-growing healthy tissues. Altogether, these adverse effects lead to
lowering the quality of life of the patient.

6,20–23

In contrast, nanomedicine provides nanoscale

platforms that can be tuned to enhance selectivity, efficiency (at lower dosages), stability, and
solubility.

24–26

Various nanomedicine formulations have been designed and pre-clinically

evaluated over the years. Moreover, with the advancement of multifunctional (smart) nanocarriers,
the applications of nanomedicine have become unprecedented. 20,27–29

2

1.2 POLYMERIC NANOPARTICLES IN NANOMEDICINE
Polymers provide versatility to obtain the required properties of an ideal nanocarrier and
excellent synthetic accessibility that allows the designer to tailor the synthesis according to enduse. 30–32 They are macromolecules formed by the covalent conjugation of one or different types
of building blocks (monomers) to construct a linear or branched chain. The monomer selection can
be made to meet specific properties in the resulting polymer. 33 There are two ways these polymers
can be used in therapeutic delivery and diagnosis purposes (ⅰ) through the conjugation with the
therapeutic agent; or (ⅱ) encapsulating the therapeutic agent in polymer aggregates.20,34 Polymerdrug conjugates, polymer-protein conjugates, and dendrimeric drugs are among the most clinically
relevant formulations obtained via the conjugation method.

20,35

This approach helps to increase

the molar mass of the therapeutic agent and assure prolonged circulation times, and enhance the
solubility of hydrophobic therapeutics. 36,37 However, the lack of versatility limits the applications
of this strategy because only a handful of therapeutic/imaging agents could preserve their original
properties after a covalent conjugation.

36,38–40

On the other hand, encapsulation provides

accessibility for a vast range of guest molecules. This method utilizes noncovalent interactions
such as hydrophobic interactions, hydrogen bonding, and electrostatic interactions to load the guest
molecule into a polymeric nanoaggregate. 6,41–43 As the therapeutic/imaging agent does not involve
a direct chemical reaction to load or release; this approach is effective in synthetic and therapeutic
efficacy aspects. In this approach, the properties of the polymeric nanoaggregate directly affect the
success of the method. The selected polymeric system should be from stable nanoaggregates with
biocompatible morphologies and sizes while encapsulating the therapeutic agent. Additionally, it
should be equipped with targeting and releasing strategies. 32,34,44

3

Over recent decades, self-assemblies of block copolymers (BCPs) have been extensively
studied as smart nanocarriers.

42,45

Such attention has been taken by the potential of BCPs to

produce narrow molar mass distributions and dedicated segments (blocks) for inducing phase
separation to form highly ordered self-assemblies. In addition, the structure and properties of each
block can be engineered to achieve specific properties such as biocompatibility, targeting,
biomimetic morphologies, and enhanced permeability towards hydrophobic molecules.46–48
Amphiphilic BCPs is an attractive variation of BCPs that contains discrete hydrophobic
and hydrophilic blocks. They possess desirable properties over other BCPs as they self assemble
into nanoaggregates in an aqueous medium to decrease the interfacial area of the hydrophobic
block to decrease the interfacial free energy.

45,49,50

Morphologies of these self-assemblies are

directly related to the physical properties of each block. According to the theories of self-assembly,
the influence of inherent molecular curvature on the packing of BCP chains leads to these
morphological outcomes.

51

The packing parameter (p), established by Israelachvili et al. and

defined in Eq 1, combines copolymer properties to predict the curvature and the prepared
morphologies. 52

𝑝=

𝑣
𝑎0 𝐿𝑐

(1)

In eq 1, v is the volume of the hydrophobic chains, ao is the optimal area of the head group,
and Lc is the hydrophobic chain length. As a general rule, when p is less than 1/3 spherical micelles,
between 1/3 and 1/2 cylindrical micelles, between 1/2 and 1 to vesicles/polymersomes are favored.
By taking advantage of this phenomenon, BCPs can be engineered to achieve the desired
morphologies by simply changing the hydrophobic to hydrophilic weight ratio. 53–56

4

When focusing on the desired morphologies for a nanocarrier, polymeric micelles (PMs)
and polymeric vesicles (polymersomes) are prominent.

32,57,58

PMs are spherically shaped

nanoaggregates that comprise a hydrophobic core (assembly of hydrophobic blocks) and a
hydrophilic corona (outer shell). This morphology provides an optimal drug delivery system for
therapeutic agents. The hydrophobic core is capable of carrying hydrophobic molecules with high
loading capacity, and the hydrophilic shell enhances the stability of the nanocarrier in the blood
by providing steric protection.

32,45,59

Additionally, PMs are considerably larger than liposomes

and other polymer-drug conjugates. This allows the transfer of more therapeutic agents than other
polymer−drug conjugates and can release the drug in a more controlled manner.

60–63

Genexol®-

PM, paclical, lipotecan are some of the Food and Drug Administration (FDA) approved PM-based
therapeutics for cancer. 42

Figure 2. Formation of polymeric micelles and polymeric vesicles (polymersomes) by amphiphilic
block copolymers.

5

PMs also possess relatively low critical aggregation concentration (CAC) values that lead to
enhanced stability in blood when compared to liposomes and other surfactants.

64–66

CAC is the

minimum concentration required to form the nanoaggregates and considered as one of the basic
parameters that define the thermodynamic stability of a nanoparticle. Lower CAC values indicate
higher thermodynamic stability. However, research has shown that in vivo applications of
conventional PMs fail to provide their projected efficacy, mainly due to premature disintegration
during circulation. This is unfavorable and dangerous in the therapeutic delivery aspects since the
systemic dilution of micellar solution results in the precipitation of hydrophobic drugs. 20,67,68
On the other hand, polymersomes (polymeric vesicles) made of biodegradable amphiphilic
BCPs have shown superior physicochemical properties compared to PMs.

69

The morphology of

polymersomes is very similar to that of a liposome, where a bilayer membrane surrounds the core.
Bilayer membrane is composed of hydrophobic blocks and has a hydrophilic corona both inside
and outside of the sphere (Fig. 3). As a result, polymersomes can encapsulate not only hydrophobic
therapeutics (i.e., in the hydrophobic bilayer) but also hydrophilic therapeutics, proteins, enzymes,
peptides, or nucleic acid fragments in the hydrophilic layers. Polymersomes have been shown to
exhibit enhanced stability, extended circulation times, and slow release of the therapeutic
agent.42,60,70,71
The reason for this high stability and longer retention time is based on their low CAC
values (i.e., relative to PMs) and the slow exchange dynamics of the amphiphilic block copolymers
that form the nanoparticle. 72–74 Furthermore, the improved colloidal and mechanical stabilities of
the polymersomes make them a better candidate than PMs to be utilized in nanomedicine. 48,75

6

1.3 SMART NANOCARRIERS AND SMART CANCER THERAPY
Smart nanocarriers (SNCs) are engineered to achieve additional functionalities not
accessible with simple therapeutic carriers. In general, these nanocarriers possess the following
properties: (ⅰ) ability to avoid biological barriers such as the reticuloendothelial system cleansing;
(ⅱ) target specific accumulation; (ⅲ) stimuli-responsive mechanism to release the payload at the
target site; and (ⅳ) ability to co-deliver therapeutics and other molecules such as
imaging/contrasting agents, genetic materials, and labeling agents.

76–80

Nanocarriers can be

engineered to adopt one or more of these properties relevant to the application.
Target-specific drug/gene delivery for cancer and early-stage tumor diagnosis is among the
highest priority research areas where the concepts of SNCs are extensively adopted. 34There have
been numerous reported attempts on combination therapy, concurrent therapy and imaging,
external stimuli-responsive release, and active/passive targeting using SNCs for cancer treatment.
81–84

Most of these approaches exploit the unique microenvironment and pathophysiology of the

tumor vascular system. Cancer cells possess rapid growth rates, which demand speedy
vascularization.39,85,86 This leads to defective vascular architecture with wide gaps between
endothelial cells that are more permeable to nanoscale particles/molecules than normal tissues.
Particles between 20-200 nm are easily accessible to the cancerous tissue through these gaps (Fig.
2). Furthermore, the absence of an efficient lymphatic drainage system in the tumor results in the
accumulation of these particles within cancer cells. This effect is called the enhanced permeability
and retention (EPR) effect. 87–89 By engineering nanoparticles within the EPR size range, they can
be passively accumulated in tumors after intravenous administration.

7

Figure 3. Passive targeting and active targeting in the tumor microenvironment.34
The tumor microenvironment is the other important factor for passive targeting. As cancer
tissues lack a proper vascular system, anaerobic cellular respiration becomes more prominent than
aerobic respiration resulting in an increased concentration of lactic acid (pH ≤ 5.4). 90 This low pH
can be employed to release the active drug into target tissues with the aid of pH-sensitive release
mechanisms. Redox responses are another type of stimulus that comes in handy for passive
targeting. Glutathione (GSH) is a tripeptide present in mammalian cells, which has a tenfold higher
concentration in cancer cells than in normal tissue and 100 fold higher concentration than blood
plasma. 91,92GSH can reversibly reduce disulfide bonds in a molecule, thereby have the potential
to break a nanoparticle that has disulfide crosslinks and promote drug release. 93
8

Active targeting involves the conjugation of a targeting ligand to the surface of the
nanocarrier. The targeting ligands can be antibodies, antigens, proteins, nucleic acids,
carbohydrates, and vitamins.

34

Two principal strategies are possible for active targeting: (ⅰ)

targeting the cancer cell, 94 and (ⅱ) targeting tumor endothelium. 95 Cancer cell targeting is more
of a direct approach where overexpressed receptors are utilized. Transferrin receptors, folate
receptors, glycoproteins, epidermal growth factor receptor are highly overexpressed in cancer cells
thus are employed for active targeting. 96–98 On the other hand, disturbing the tumor endothelium
leads to cell death due to insufficient oxygen and nutrient supply. Judah Folkman first proposed
this strategy in 1971.

99

Vascular endothelial growth factor receptor, vascular cell adhesion

molecule-1 (VCAM-1), and matrix metalloproteinases have been commonly utilized for
developing endothelium targeting nanocarriers. 100,101 In addition to taking advantage of the EPR
effect and tumor microenvironment for smart cancer therapy, it is also possible to trigger-release
the payload using external stimuli, such as radiation, temperature, ultrasound, and magnetic fields.
102

When considering all the facts discussed earlier, it is evident that the nanocarrier should be
robust and synthetically accessible. Furthermore, the synthetic method should allow the strategical
control of size, morphology, and surface properties. Consequently, only a handful of nanocarriers
meets the requirements to perform as a smart nanocarrier. 6,20

1.4 ENGINEERING POLYMERS AS SMART NANOCARRIERS
Focusing on the facts discussed in Chapters 1.2 and 1.3, it is evident that polymer
chemistry provides accessible and efficient platforms for nanomedicine. Polymeric nanoparticles
have demonstrated exceptional advantages for incorporating a wide range of guest molecules and
9

overcoming biological barriers.

29,103–105

Moreover, polymer chemistry allows engineering and

fine-tuning of nanoparticle structure to attain the desired properties.
When engineering polymers to perform as smart nanocarriers, selecting the polymer
materials with desired properties is the most crucial task. Foreseen nanostructure outcomes such
as biocompatibility, biodegradability, mechanical stability, morphology, size, polydispersity,
tailorability, and loading/encapsulation efficiencies are highly dependent on the properties of the
polymers present in each block. The essential requirement is to select materials that can preserve
the amphiphilicity (for self-assembly), biodegradability, and biocompatibility. According to the
list of Lu et al., polyethylene glycol (PEG), poly-lactic-acid-co-glycolic-acid (PLGA), polyvinyl
alcohol (PVA), polyvinyl pyrrolidone (PVP), polyethylene (PE), and aliphatic polyesters are
common synthetic polymer materials in nanomedicine applications. 42,50,69
Aliphatic polyesters have been studied for several decades in biomedical applications due
to their biodegradability and biocompatibility.

69

Several factors are essential when looking at

biodegradable materials. Not only the material itself, but also the resulting end-products should be
nontoxic. The material should be mechanically stable to fulfill the task, and the degradation rate
should line up with the treatment completion time. When considering these aspects, polyesters are
advantageous owing to their tunability in crystallinity, thermal properties, degradation rates, and
mechanical strength. 42,69 In addition, the polymer backbone should provide synthetic accessibility
towards introducing substituents.
Polycaprolactone (PCL), polylactide (PLA), polyglycolide (PGA), polydioxanone (PDO),
polybutyrolactone (PBL), and polyvalerolactone (PVL), and their combinations are polyesters in

10

general use. However, PCL, PLA, and PGA are the most applied polyesters. Properties and current
medical applications of these polyesters are summarized in Table 1. 106

Table 1. Properties of commonly used polyesters

Structure

Polylactid
e (PLA)

Poly
caprolacto
ne (PCL)

Polyglycol
ide (PGA)

In-vivo
degradation

Tg, Tm (℃)

Applications

(60–65),
(150-160)

Fracture fixation,
interference screws,
meniscus repair,
reconstructive
surgeries, Vascular
grafts

50% in 4
years
(hydrolytic
degradation)

(- 60), 60

Dental implants, tissue
repair, hybrid tissueengineered heart
valves, surgical
meshes, cardiac
patches

100% in 6–
12 months
(enzymatic
/nonenzymatic
hydrolysis)

(35-40),
(225-230)

Tissue-engineered
vascular grafts,
artificial skin, wound
healing

100% in 12–
16 months
(enzymatic
hydrolysis)

When looking at the biomedical applications, these polyesters have proven their candidacy
for safe use in the human body. PLA and PCL are among the most widely used polymers in the
drug delivery field. 107,108 PLA is often copolymerized with PGA to form poly(lactide-coglycolide)
(PLGA). PLA has two enantiomeric forms; poly(D-lactic acid) (PDLA) and poly(L-lactic acid)
(PLLA). 109 There is a racemic PLA, which is amorphous, while pure PLLA and PDLA are highly
crystalline. When it comes to biomedical applications, PLLA is often used because it is known to
be more biocompatible. 69 On the other hand, PCL is widely used in drug delivery design because
of its superior mechanical properties and relatively slower degradation rates. 110,111 Furthermore,
11

PCL allows introducing substituents onto the polymer chain or the monomer (α or γ position).
112,113

This tunability enables engineering polymers to achieve the desired thermal and mechanical

properties and hydrophobicity. Prodrugs, targeting moieties, and crosslinkers can also be
introduced as these substituents. 114
As amphiphilicity is necessary to form polymeric vesicles as therapeutic delivery systems,
PLA or PCL requires a hydrophilic block to become amphiphilic. PEG has been extensively used
as the hydrophilic block with these polyesters.

50

Nanoaggerates of PEG-PCL/PLA block

copolymers have proven their potential in drug delivery applications. Qian et al. demonstrated
combination loading of paclitaxel (an anticancer drug) and β-lapachone (a cytotoxic agent) in
PEG-PLA micelles. These drug-loaded micelles showed enhanced cytotoxic effects on NQO1overexpressing cancer cells.

115

Similar studies have been carried out not only with PEG-PCL

diblock copolymers, but also with triblock copolymers and star block copolymers.

69,116,117

However, conventional linear block copolymers fall behind in providing the optimal mechanical
stability to stand against the bloodstream dilution. Even though the CAC values of these
nanoaggregates are low enough to handle in-vitro cell culture dilution, the equilibrium tends to
shift towards free chains in the systemic circulation. This demands improvements to the structure
of these amphiphilic block copolymers to gain enhanced mechanical stability. 20
Dendrimers are another class of polymers that have been developed parallelly to linear
block copolymers. Polymers with radially symmetric tree-like braches are known as dendrimers.
They consist of three distinct parts: the core, branching dendrons, and surface-functionalized
groups (Fig. 4a). The surface functional groups on the dendrimer surface govern the
physiochemical properties of the dendrimer. These surface groups can be used to tune the

12

hydrophobicity or hydrophilicity of the system. 118 Through a well-controlled synthesis, dendritic
nanocarrier systems can be designed with a hydrophobic core and a hydrophilic surface that

Figure 4. The general structure of (a) a dendrimer (b) a linear dendritic block copolymer (LDBC).
G1, G1, G3 denote 1st generation, 2nd generation, and 3rd generation, respectively.
resembles a micellular structure. 2,2-Bis(hydroxymethyl)-propanoic acid-containing polyester
dendrimers have demonstrated the intracellular release of Doxorubicin via hydrolysis mediated
degradation.

34,119

Polyamidoamine (PAMAM) dendrimers are also known for their

biocompatibility and tunability. 120–122 Yang et al. evaluated the potential of PEGylated PAMAM
dendrimers functionalized with cyclic arginine–glycine–aspartate hexapeptide and penetratin, as
nanocarriers in ocular delivery.

123

They observed these dendritic nanoparticles are active in the

ocular posterior segment for more than 12h of administration. Furthermore, multifunctional
PAMAM dendrimers with folic acid targeting moieties along with an imaging agent (fluorescein
isothiocyanate) and a therapeutic agent (Taxol) has been developed. 34 Nonetheless, conventional
dendrimers exhibit rapid systemic clearance by the immune system and lower penetration into
cancer cells. Also, dendrimeric nanocarrier synthesis is more challenging compared to linear
polymers. 29,124
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When considering all the facts discussed so far, polymer-based nanocarriers have proven
to be highly promising in nanomedicine applications. However, when they perform as individual
polymeric systems, each of these has its drawbacks. These shortcomings impede the individual
polymeric system to provide expected efficiency as a smart nanocarrier system. As a result, hybrid
systems of different polymeric materials have been proposed. 125,126 The purpose is to combine the
favorable properties of each candidate and scale down the unfavorable properties. This can be
considered as a smart approach to design next-generation smart nanocarriers.

1.5 AMPHIPHILIC LINEAR DENDRITIC BLOCK COPOLYMERS (LDBCS) AS NEXTGENERATION BIOMATERIALS
With the emerging concept of hybrid biomaterials, there have been diversified hybrid
architectures designed. Fréchet et al. introduced the liner dendritic block copolymers (LDBCs)
concept in the early 1990s, 127 where a linear polymer is conjugated to a dendritic unit in a range
of different configurations (Fig. 4b). These systems can combine the expedient properties of both
linear and dendritic (i.e., branched) macromolecules, which results in a composition of segments
with different molecular architectures and chemical properties. When amphiphilicity is introduced
to these polymers, various types of supramolecular aggregates in water are observed. The size,
morphology, and mechanical properties of these aggregates depend on the mass ratio between the
hydrophilic and hydrophobic moieties. 127 When considering a perfect dendrimer, the molar mass
is fixed to an exact predefined value. The LDBC architecture provides the flexibility to synthesize
any molecular weight with any desired ratio. Compared to traditional copolymers, the
nanoaggregates formed from LDBCs possess enhanced mechanical properties and high
monodispersity. 128,129 The properties of LDBC systems will be discussed in detail in Chapter 2.

14

As discussed in Chapter 1.4, aliphatic polyesters (especially PLA and PCL) and PAMAM
dendrimers are individually associated with favorable properties as nanocarriers. The polyesters
employed here are hydrophobic, and PAMAM is hydrophilic, making them perfect candidates to
design an amphiphilic smart nanocarrier system. However, challenges in synthetic feasibility have
hindered the widespread adoption of amphiphilic LDBCs due to the distinct solubility of the
blocks, steric effects of the branched block on copolymerization, and the challenges in the
purification of end products. 130,131 In addition to these difficulties, the prediction of the properties
of the nanoaggregates concerning the traditional mass ratio heuristic used with linear polymers
does not accurately support these nonlinear, anisotropic systems. 132
In regard to the synthesis, characterization, and applications of these polymers, the number
of published articles in which PAMAM and polyesters have been combined as linear dendritic
block copolymers are few.

133–136

However, the micellar nanoparticles prepared in those studies

faced stability challenges, and stable nanoparticles (NPs) could only be prepared at high PAMAM
weight ratios.

137

Although the studies generated promising materials for potential biomedical

applications, the design and methodology lacked the synthetic versatility to yield high performing
materials.
This work will outline a systemically different approach to exploring the potentials of merging
PAMAM and polyesters into a single polymer. Chapter 2 illustrates a facile and comprehensive
synthetic methodology for the preparation of polyester-PAMAM (i.e., polyester: PLA
(hydrophobic) and PAMAM (hydrophilic)) polymers and studying the properties of the
nanoaggregates which are formed in water by those polymeric systems. Based on the established
synthetic strategies and characterization methods (Chapter 2), the studies were driven towards a
system with enhanced biocompatibility and synthetic feasibility. The nano aggerates formed with
15

this system were evaluated for their cytotoxicity and successfully used as nanocarriers in in-vitro
near infra-red (NIR) imaging and photothermal therapy (Chapter 3). After proving the potential
as smart nanocarriers for nanomedicine, structural developments were introduced to enhance the
mechanical stability and hydrophobic therapeutic loading efficiency (Chapter 4). The results of
this work have created robust and versatile synthetic strategies to engineer polyester-PAMAM
LDBCs, new knowledge in the self-assembly of amphiphilic LDBCs, next-generation
biocompatible nanocarriers for therapeutic delivery, and strategies to develop these nanocarriers
to the next level.
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CHAPTER Ⅱ: SYNTHESIS AND CHARACTERIZATION OF POLYLACTIDEPAMAM “JANUS-TYPE” LINEAR-DENDRITIC HYBRIDS
This chapter adapted from Chandrasiri, I. , Abebe, D. G., Gupta, S. , Williams, J. S., Rieger,
W. D., Simms, B. L., Yaddehige, M. L., Noh, Y. , Payne, M. E., Fortenberry, A.W., Smith, A. E.,
Ilavsky, J. , Grayson, S. M., Schneider, G. J. and Watkins, D. L. (2019), Synthesis and
characterization of polylactide‐PAMAM “Janus‐type” linear‐dendritic hybrids. J. Polym. Sci. Part
A: Polym. Chem. doi:10.1002/pola.29409
This project is a collaborative work between Dr. Schneider, G. J., Dr. Grayson, S. M., and Dr.
Smith, A. E. The synthesis and characterization of LDBCs were performed by Chandrasiri, I., and
Abebe, D.G. Synthesis and characterization of macroinitiator were done by Rieger, W. D., Simms,
B. L. Thermal and CAC analysis were performed by Williams, J. S. SAXS analysis was performed
by Gupta, S.

ABSTRACT
Herein is presented a facile and comprehensive synthetic methodology for the preparation
of polyester-polyamidoamine (PAMAM) (i.e., polyester: polylactide [PLA] (hydrophobic) and
polyamidoamine, PAMAM [hydrophilic]) polymers. A library of PLAPAMAM linear dendritic
block copolymers (LDBCs) in which both L and D, L polylactide were employed in mass ratios
of 30:70, 50:50, 70:30, and 90:10 (PLA: PAMAM) were synthesized and analyzed. When placed
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in aqueous media, the immiscibility of the hydrophilic and hydrophobic segments leads to
nanophase-segregation exhibited as the formation of aggregates (e.g., vesicles, worms, and/or
micelles). By employing both stereochemical configurations of PLA, the differentiation in mass
ratios of PLA-PAMAM aided in elucidating the structure-property relationships of the LDBC
system and provided a means toward the control of nanoparticle morphology. Transmission
electron microscopy and dynamic light scattering afford the size and shape of the nanoparticles
with diameters ranging from 10.6 for low mass ratios to 122.4 nm for high mass ratios of
PLA-PAMAM and positive zeta-potential values between +24.7 mV and +48.2 mV. Furthermore,
small-angle X-ray scattering (SAXS) studies were employed to obtain more detailed information
on the morphological assemblies constructed via direct dissolution. Such insights provide a
pathway toward nanomaterials with unique morphologies and tunable properties deemed relevant
in the development of next-generation biomaterials.

2.1 INTRODUCTION
As described in Chapter 1, LDBCs are have proven their potential as nanocarriers in smart
therapeutic delivery. Considering the components that constitute the molecular framework of
LDBCs and contribute to the properties of the resulting nanostructure, a diverse range of building
units can be investigated for further applications. Of particular interest is that of polyamidoamine
(PAMAM) and polyesters. PAMAM is a hydrophilic dendrimer comprised of an amide backbone.
Its structural cavities afford opportunities for encapsulation of small molecules via noncovalent
interactions,

138,139

mainly hydrogen bonding.

140

The terminal free amine groups provide a

positive-charge surface density suitable for biological applications (i.e., cell binding and
endocytosis). Naturally, PAMAM has found wide interest as a drug delivery vector, and there is a

18

large body of established work in terms of its drug encapsulation, transfection efficiency, and
delivery capacity. 141
In a review of the type of linear polymers utilized in LDBCs, a limited few have been
reported—those

of

which

include

poly(ethylene

poly(styrene), and poly (propylene oxide).

142

oxide),

poly(2-methyl-2-oxazoline),

Most notable are those LDBCs created with the

biodegradable, biocompatible polyester, PLA. PLA is one of the few hydrophobic polymers that
can have its stereochemical structure modified by polymerizing the D or L form of the monomer.
143

It is also one of the most well-characterized and widely applied polymers for biomedical

applications.
In regards to the applications of these unique polymers, the number of published articles in
which PAMAM and polyesters have been combined as linear diblock copolymers are few in
number.

133,136,144,145

Qiao et al. synthesized PAMAM-PLLA LDBCs by ring-opening

polymerization (ROP) of D,L-lactide using stannous octoate (Sn(Oct)2) with a half-generation
PAMAM dendron as the macro-initiator.

137

The micellar nanoparticles prepared in their study,

however, faced stability challenges and stable nanoparticles (NPs) could only be prepared at high
PAMAM weight ratios.

137

Although the study generated promising materials for potential

biomedical application, the design and methodology lacked in the synthetic versatility that is
needed to yield high performing materials.
By undertaking a systemically different approach to explore the potentials of merging
PAMAM and polyesters into a single polymer, herein is presented a facile and comprehensive
synthetic methodology for the preparation of polyester-PAMAM (i.e., polyester:PLA
(hydrophobic) and PAMAM (hydrophilic)) polymers. Aspiring to develop next-generation drug
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delivery systems (DDS) (Fig. 5), it is our belief that the combination of these polymers—which
each have individually long pedigrees in material science—can lead to the establishment of unique
materials through compositional and architectural control. A library of 30, 50, 70, and 90 (i.e.,
weight percentage with respect to PLA) LDBCs of both L and D, L were synthesized and analyzed
using nuclear magnetic resonance (NMR), gel permeation chromatography (GPC),
thermogravimetric analysis (TGA), and differential scanning calorimetry (DSC). Different mass
ratios of PLA-PAMAM using both stereochemical configurations of PLA were synthesized in
order to elucidate the structure–property relationships (i.e., resulting structure in respect of
polyester type and mass ratio) of the LDBC system; thus, facilitating control of nanoparticle size
and shape. Nanoparticles were then formed in aqueous media, and the resulting structures were
studied by dynamic light scattering (DLS), transmission electron microscopy (TEM), and smallangle X-ray scattering (SAXS).

Figure 5. Graphical illustration of (a) Janus type (linear-dendritic block copolymers) LDBCs made
of polyamidoamine (PAMAM) and polylactide and (b) expected bilayered vesicles formed in
water by the LDBCs.
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2.2 RESULTS AND DISCUSSION
2.2.1 DESIGN AND SYNTHESIS OF POLYESTER-PAMAM LDBCS
An illustration of the PLA-PAMAM LDBCs of study is shown in Figure 5a. The hydrophilic block,
which consists of dendritic PAMAM, was chosen due to its synthetic accessibility, allowing
various functional groups to be readily incorporated. Possessing a hyperbranched polymeric
structure, the backbone of PAMAM mimics the polypeptide nature of many biological species
present in the body.

141

Such a structure renders the PAMAM portion more biocompatible than

other traditional dendrimeric systems. The opposite is the hydrophobic polyester block, either
PLLA (L) or PDLLA (DL). These hydrophobic polymer chains drive the self-assembly of the
nanostructures. These were systematically chosen for two purposes: (a) extended pedigree as
biocompatible and biodegradable biomaterials and (b) accessible range of thermal and mechanical
properties (i.e., crystalline vs. amorphous). 143
By utilizing the 1:1 mixture of D and L-lactide monomer, the heterotactic PDLLA is achieved.
This polymer is amorphous and does not exhibit a melting temperature (Tm). Alternatively, the
pure L-lactide monomer yields the isotactic PLLA, which is semicrystalline possessing a Tm above
180 degrees.

146

The differences between crystalline PLLA and amorphous PDLLA provided an

opportunity to probe the effects of monomer composition on the morphology and thermodynamic
properties of the resulting self-assembled nanostructure. Boc-protected PAMAM (G3) possessing
a hydroxyl focal-point was synthesized in five steps (Scheme 1) and used as the macroinitiator
(HO-G3Boc) for ROP of either L- or DL-lactide monomer to yield LDBC precursors, L-G3Boc
and DL-G3Boc in mass ratios of 90:10, 70:30, 50:50, and 30:70 PLA to PAMAM (Scheme 2).
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Scheme 1. Synthesis of PAMAM – G3 – Boc.

Under mild conditions, the Boc protecting group is readily removed using TFA to yield the target
LDBCs, L-G3 and DL-G3. While others have been limited to <50 wt % hydrophobic content in
order to form stable aqueous nanoparticles,

137

the amine protection/de-protection approach

utilized here allowed us to prepare copolymers containing up to 90 wt % hydrophobic polymer
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while still possessing enough hydrophilic character to self-assemble into stable nanostructures in
aqueous solution.
In employing a dendrimer first approach, the characterization of the macroinitiator, HOG3Boc, is critical. The Boc group was installed to prevent ring-opening polymerization (ROP) off
of the terminal amines and additional side reactions at the periphery of the PAMAM dendron.
MALDI-TOF mass spectrometry was used to validate the structural integrity of the PAMAM
dendron and reactivity of the hydroxyl focal point as steric inhibition has been a reported challenge
for the synthesis of LDBCs.32,33 For the latter, HO-G3Boc exhibiting a mass to charge ratio of
2481 m/z [M + Na]+ was treated with acetic anhydride (Fig. 36, Appendix A). The product was
purified and analyzed via mass spectrometry to reveal a difference in mass of 42 m/z corresponding
to the addition of an acyl group at the focal-point and sole reactivity of the hydroxyl group on HOG3Boc (Fig. 37, Appendix A).
Verification by both 1H NMR spectroscopy [Fig. 6(a)]and mass spectrometry (Fig. 38,
Appendix A) supported further use of HO-G3Boc in ROP of L- and DL-lactide. Reactions were
conducted with 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU) as the catalyst in anhydrous
chloroform and purified via precipitation in a mixture of diethyl- ether, hexane and methanol
(15:5:1). It is imperative to note that the ROP step was optimized for DBU as the catalyst rather
than the traditional Sn(Oct)2.

147

During synthesis development, the concentration of Sn(Oct)2

required to achieve >90% monomer conversion was much higher, particularly at higher PAMAM
weight ratios, than the 5% (per hydroxyl initiator) previously reported. 137 We observed a mere 8%
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Scheme 2. Synthetic route for LDBCs by ring-opening polymerization of lactide initiated by HOG3Boc macroinitiator.

monomer conversion for our copolymers with 5% catalyst loading and required ~20% Sn(Oct)2 to
reach monomer conversion >90%. When the polyester weight ratio is higher, for example, 70:30,

Figure 6. NMR comparison of the (a) macroinitiator HO-G3Boc, (b) LDBC precursor 70-DL-G3Boc and (c) amphiphilic LDBC 70-DLG3 as a reverse micelle. Peaks from 2.19 ppm to 3.69 ppm
refer to the protons signals for PAMAM-G3-Boc (Fig. 31, Appendix A). The resonance peaks
corresponding to the primary and tertiary hydrogens on the liner polylactide chain appear at 1.57
and 5.15 ppm (Fig. 32, Appendix A).
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slightly less Sn(Oct)2 is required (~15%) to drive lactide monomer conversion to >90%. Rationale
for such high loading of Sn(Oct)2 is not fully understood; however, it is feasible to assume catalyst
deactivation or sequestration through interactions with the PAMAM macroinitiator is the cause.
Polymerization kinetic studies are actively on-going with a focus on understanding initiation,
propagation, and competing events such as depolymerization and catalyst deactivation. Because
the higher loading of a potentially toxic metal catalyst is counter-productive to the biomedical
driven application of the study, a number of other organometallic (zinc undecylenate) and organic
[4-dimethylaminopyridine, 1,8-Diazabicyclo(5.4.0)undec-7-ene (DBU), triazabicyclodecene]
catalyst systems previously reported for ROP of lactides were screened (Table 6). 147–150 DBU was
found to be the most efficient catalyst, leading to near quantitative monomer conversion at all
weight ratios investigated. In addition, the use of DBU afforded further advantages, such as
reduced reaction time (4 h), mild reaction conditions (25 ℃), and quantitative removal of the
resulting DBU-benzoate salt, which eliminates the presence of residual cytotoxic catalyst within
the polymer.
As shown in Figure 6, an overlay of NMR spectra shows characteristic peaks of PAMAM
(2.19–3.69 ppm) and PLA (1.57, 5.15 ppm). Both segments are present in the spectrum of the
coupled product for precursor 70-DL-G3-Boc where 70 denotes the percentage of DL-lactide
composing the LDBCs [Fig. 6(b)]. Boc-protected LDBCs show high solubility in common
solvents such as chloroform and THF; however, upon deprotection of the PAMAM block with
TFA to yield 70-DL-G3, solubility dramatically decreased due to the formation of NH3+ terminal
groups (Scheme 2). NMR spectra of deprotected 70-DL-G3 (Fig. 6c; chloroform-d) give indirect
evidence of solvent-driven aggregation by the disappearance of resonance peaks for PAMAM,
whereas PLA peaks remain visible. No precipitation is observed in the chloroform-d solution,
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which suggests the formation of a reverse-micelle where PAMAM is shielded from the solvent
(i.e., micelle core) and PDLLA acts as a stabilized shell. Others have reported such analyses to
give indirect confirmation of a covalently linked copolymer with both hydrophilic and
hydrophobic components. 151

2.2.2 MOLECULAR WEIGHT ANALYSIS OF LDBCs
Aiming to correlate feed ratios to that of molecular weight and degree of polymerization,
further characterization of the products was required. The precursors were studied due to the
limited solubility of the deprotected LBDCs and tabulation of the results are given in Tables 2 and
in Appendix A Tables 7-8 and molecular weight calculations are given in the Appendix A Table
8. Initially, MALDI and GPC presented a unique challenge for these systems. In the case of
MALDI, ionization of the PAMAM species only occurred in a small subset of solvent/matrix
combinations that were tested. Such challenges have been noted in the literature. 152–154 In contrast,
GPC gave better results, particularly for precursors with a greater mass percentage of PLA (i.e.,
90-DL-G3Boc, 70-DL-G3Boc, 90-L-G3Boc, and 70-L-G3Boc). As the calibration curve was
created with a linear polystyrene standard, the hydrodynamic volume of these polymers did not
correlate perfectly, as dendrons are more compact. For LDBCs with a greater linear (i.e., PLA)
portion, the peaks displayed a more Gaussian nature, whereas in systems that had a higher weight
percentage dendritic portion (i.e., 50-DL-G3Boc, 30-DLG3Boc, 50-L-G3Boc, and 30-L-G3Boc),
there was a deviation from the normal distribution, with shoulders appearing adjacent to the major
peak (Figs. 40, 41, Appendix A). Upon changing the solvent from THF to DMF, an improved
chromatographic behavior is seen presumably due to increased solubility of LDBCs with higher
PAMAM ratios in the more polar solvent (Appendix A).
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Table 2. Molecular weight characterization of PLA-PAMAM LDBCs of varying weight ratios by
GPC with DMF as the elution solvent; chromatographs chown in Figs. 38 and 39, Appendix A.
Mth

Mn

Mw

g mol-1

g mol-1

g mol-1

90-L-G3Boc

17,465

12,084

20,659

1.71

70-L-G3Boc

6350

8,189

12,012

1.52

50-L-G3Boc

4127

5,205

6,565

1.28

30-L-G3Boc

3175

3,862

4,248

1.10

90-DL-G3Boc

17,465

15,303

24,203

1.58

70-DL-G3Boc

6350

8,255

11,688

1.47

50-DL-G3Boc

4127

5,540

6,972

1.28

30-DL-G3Boc

3175

4,402

4,941

1.13

LDBCsa

Ð

a

Notation of L-G3 and DL-G3 denotes LDBC composition where L: PLLA or DL: PDLLA linked
to a G3 PAMAM with weight percentage of lactone attributed and Mth, Mn, Mw, Ð denote
theoretical molar mass, number average molar mass, weight average molar mass and dispersity,
respectively.

2.2.3 THERMAL ANALYSIS
Thermal analysis via TGA (Fig. 42, Appendix A) and DSC (Fig. 7) was achieved using
deprotected LDBCs. In this case, all polymers have NH3+ end groups, unless otherwise noted. The
amine end groups are expected to have some effect on thermal stability due to the possibility of
intramolecular hydrolysis or hydrogen bonding. DSC was done up to 180 ℃ in all cases, which is
approximately the onset of decomposition according to TGA. Unfortunately, Tms were not
attainable for L-G3. Thermal stability followed the general trend of increasing as the total
molecular weight increased (Table 7). LDBC 90-L-G3 exhibits a higher decomposition
temperature than that of 90-DL-G3 presumable due to it crystalline nature.

109,155

The one

exception was 30-L- G3, which displayed an increase in thermal stability versus 50-L-G3. All L27

G3 LDBCs except 90-L-G3 showed a slight decrease in thermal stability before the decomposition
point, which is hypothesized to be due to the more hygroscopic nature of these LDBCs.

Figure 7. DSC traces of (a) L-G3 and (b) DL-G3 LDBCs under heating at 20 ℃ min−1 under a
nitrogen atmosphere.
Glass-transition temperature (Tg) decreased as a function of the polyester type and hydrophobic
mass ratio. LDBCs 90-L-G3 (57.7 ℃) and 90-DL-G3 (52.3 ℃) exhibit thermal features that are
more representative of PLA while that of 30-L-G3 (39.4 ℃) and 30-DLG3 (32.6 ℃) correspond
to that of PAMAM (Table 9). These results are reasonable as both LDBC sets comprised majority
PLA or PAMAM, respectively. Polymers 70-DL-G3 (39.4, 50.4 ℃), 50-DL-G3 (36.5, 46.7 ℃),
and 70-L-G3 (41.2, 53.7 ℃), 50-L-G3 (broaden ~39.6 ℃) exhibited multiple Tgs. By comparing
the thermograms in Figure 7, it appears that 70 and 50% hydrophobic derivatives likely have
similar volumes between the hydrophilic and hydrophobic regions, resulting in contributions from
both polymers being observable at the Tg. 156
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2.2.4 SELF-ASSEMBLY AND MORPHOLOGY
Direct dissolution resulted in nanoparticles for LDBCs up to a 70–30 hydrophobic–
hydrophilic mass ratio. Re-dispersion in water from the dry state was almost instantaneous,
requiring little to no agitation. This observation is consistent with the variations in the hydrophilic
character of the PAMAM dendron used in previous studies 137 where the ionic nature of the

Figure 8. TEM images with utilizing uranyl formate as a contrast agent for (a) 70-L-G3, (b) 50L-G3, (c) 30-L-G3, (d) 70-DL-G3, (e) 50-DL-G3, and (f) 30-DL-G3; additional enlarged images
are located in Appendix A.
terminal amines for L-G3 and DL-G3 (NH3+) increases its hydrophilic character. When
considering the potential future of our target materials and their pharmaceutical properties, this
near instantaneous re-dispersion ability has both logistical and application advantages.
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To understand the morphology of the self-assembled nanoparticles, TEM analysis was
conducted. Additionally, the TEM observations are further confirmed by SAXS analysis (vide
infra). TEM captured aggregate morphologies of sizes (radii) ranging from 4.8 to 10.4 nm (Fig. 8
and enlarged images Figs. 49-54, Appendix A). Uranyl formate was used as a stain to increase the
contrast between the hydrophilic and hydrophobic portions. LDBC 70-L-G3 shows a distribution
of bilayered vesicles and elongated worm-like particles (Fig. 8a). 50-L-G3 produces bilayered
vesicles with radii ranging from 4.8 to 6.1 nm (Fig. 8b). 30-L-G3 yields core–shell micelles with
7.1 nm radius (Fig. 8c). In comparison with 70-LG3, 70-DL-G3 showed bilayered vesicles, but no
elongated worm-like particles were observed (Fig. 8d, 50-DL-G3 Fig. 8e) yields bilayered
vesicles, and 30-DL-G3 (Fig. 8f) produces core–shell micelles with the radii of 6.0 nm, 5.3 nm,
respectively. The formation of stable bilayered vesicles is an interesting achievement given the
molecular weight of the PLA blocks is relatively short. Previously reported vesicles composed of
block copolymers of PLA, for example, PEG-PLLA required considerably higher molecular
weights compared to our oligomeric sizes and hydrophobic weight ratios. 157
Comparable hydrodynamic volumes were determined via DLS (Table 10, Fig. 43–48,
Appendix A) with zeta potentials ranging from +24.7 mV to +48.2 mV (Table 10) for nanoparticles
prepared via direct dissolution. Such values of ± 20 to 30 mV are viewed as highly stable and are
common in drug delivery literature

158

as general guidelines classifying nanoparticle dispersions

employ zeta potential data to correlate colloidal stability. The critical aggregate concentrations
(CAC) for the LDBCs ranged from 0.91 to 9.75 mg/L (Table 11, Figs. 56–58, Appendix A),
providing further evidence of stable nanoparticles.

159

The values are comparable to those found

in the literature and correlate to the candidacy of the copolymers as potential biomaterials.
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Specifically, with the dependence of CAC on the length and weight ratio of PLA where an increase
in hydrophobicity is shown to lead to a significant decrease in the CAC value. 160

Figure 9. TEM images with utilizing uranyl formate as a contrast agent for (a and b) 90-L-G3 (c
and d) 90-DL-G3. Nanoparticles were formed via conventional nanoprecipitation method as direct
dissolution was not possible due to the high hydrophobic content.
Concerning, however, are the high zeta potentials for nanoparticles formed from 50-L-G3 and 50DL-G3. There are conflicting reports regarding the ideal surface charge required for nanoparticle
assisted drug delivery. 161,162 He et al. (cancer treatment) revealed that particles with <15 mV 163
surface charges exhibited ideal properties such as reduced macrophage uptake, longer circulation
time and higher tumor retention. 164 However, it is well established that the charge effect of cell31

uptake is cell type and surface charge dependent.

162,165

For this study, the positively charged

nanoparticles would penetrate into the cells more easily as the electronic potential of cell
membranes are generally known to be negative.

162,166

Nonetheless, high cytotoxicity due to the

presence of extremely compact amino groups at the periphery of dendrimer structures like that of
PAMAM have been well cited. 167 Considering the size distribution and surface characteristics of
nanoparticles in study, it should be noted that the surface properties of the nanostructures herein
will not only determine the uptake efficiency of these materials but may also lead to severe
drawbacks for future biological application. 168 Therefore, surface modification will be needed to
minimize the positively charged surface comprised of PAMAM. Reducing the surface charge will
aid in avoiding any impending cytotoxic effects while maintaining their potential as carriers.
By employing both stereochemical configurations of PLA, unique variations in thermal
properties, as well as morphology, are expected. Any differences in morphology are a direct result
of the varying stereoisomers of lactide (i.e., L vs. DL), leading to diverse morphologies according
to crystallinity and chain mobility.

169–171

Effects of the polyester type are apparent when

comparing the CAC, and hydrodynamic volumes for L-G3 and DL-G3 as the more amorphous
PDLLA-PAMAM LDBCs tend to have smaller CAC values and radii (Tables 10 and 11).
However, these differences are minimal. The isomeric features of PLA are more evident for
90-L-G3 and 90-DL-G3. LDBCs with >70% PLA were prepared through the conventional
nanoprecipitation method as direct dissolution in water was not possible due to the greater
hydrophobic content. 90-L-G3 produces nanostructures, which are kinetically “frozen” in
intermediate (transition) states between worms, dumbbells, and spheres (vesicles) (Fig. 9a,b). In
the subset of Figure 9a, a snapshot of a spherical bud formation is observed in which a segment of
a worm-like aggregate appears to separate off into a vesicle. 172 In contrast, 90-DL-G3 leads to the
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formation of predominately spherical nanostructures (vesicles), while transient structures are not
observed (Fig. 9c,d). When considering molecular thermodynamic effects, equilibration through
chain-exchange is not likely due to the large interfacial tension between the PLA and water. In
addition, the nanoparticles were prepared at below the Tg of PLA (~52–54 ℃). Noack et al.
postulated the crystallization of the PLLA hydrophobic block following microphase separation in
a selective solvent lead to destabilization of spherical particles, which fuse with other spherical
micelles to grow into worm-like aggregates. 173 In addition to the morphologies presented in Figs.
8 and 9, elongated micelles, cubes, and tube-like nanostructures have been observed for these
PLLA-PAMAM and PDLLA-PAMAM LDBCs under varying conditions. This work is currently
ongoing to understand the self-assembly mechanism using both computational modeling and
analytical characterization.

2.2.5 SAXS ANALYSIS
To study morphology more in detail, SAXS experiments on the nanoparticles formed via
direct dissolution were performed. An important goal in these studies was to determine bilayer
thickness in our vesicles, especially with respect to LDBCs. The thickness of the vesicle wall
strongly affects the size and stability of vesicles, and this thickness is primarily determined by the
hydrophobic portion.

174–176

Polymer vesicles have also been shown to be able to adopt a

multiwalled “onion” morphology with multiple alternating hydrophilic and hydrophobic regions.
177

This is unlikely to be observed by traditional microscopy methods and must be observed with

SAXS (Fig. 10, Table 3).
To describe SAXS data for micelles, we used a core–shell model 178,179
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𝑑𝛴
𝜙
𝑏
(𝑄) =
[𝐼
(𝑄) + 𝐼𝑠ℎ𝑒𝑙𝑙
(𝑄) + 𝐼𝑖𝑛𝑡𝑒𝑟 (𝑄) + 𝐼𝑏𝑙𝑜𝑏 (𝑄)]
𝑑𝛺
𝑁𝑎𝑔𝑔 𝑉𝑚 𝑐𝑜𝑟𝑒

(2)

Here, ϕ is the volume fraction, Vm is the total micellar volume of the block copolymer.
For Nagg, defined as the aggregation number or the number of chains attached to the core, the
terms Icore (Q) = Nagg 2 Δρcore 2 ∙ 𝑣core 2 ∙ Acore (Q)2 correspond to the scattering from the core,
with vcore as the volume of the core block copolymer (polyester block). The core contrast with
respect to the solvent is given by their respective X-ray scattering length densities (XSLD)
2

b
(Q) = Nagg ∙ (Nagg − Bcorr ) ∙ 𝑣shell ∙ Δρshell 2 ∙ Ashell (Q)2
Ishell

Δ𝜌core = 𝜌core − 𝜌solvent .

describes the scattering from the corona (PAMAM block), with 𝑣𝑠ℎ𝑒𝑙𝑙 , the volume of the shell
block copolymer and Δ𝜌shell = 𝜌shell − 𝜌solvent . The third term, IIinter (Q) = 2Δρcore ∙
Δρshell Nagg 2 ∙ Vcore ∙ Vshell ∙ Acore (Q) ∙ Ashell (Q), is due to the interference between the core and
the corona. The blob scattering from swollen corona is implemented following Svaneborg and
Pedersen52 as, Iblob (Q) = Vshell 2 Δρshell 2 ∙ P(Q)chain⁄(1 + υ̂P(Q)chain ). Here 𝐴core (𝑄) and
𝐴shell (𝑄), are the scattering amplitudes of the core (polyester) and shell (PAMAM) blocks,
respectively. The interactions between the chains in the shell is given by the blob correlation
parameter, Bcorr = 1⁄(1 + υ̂), where, 𝜐̂, is an effective virial type parameter that scales with chain
concentration in the shell.
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The corresponding polydispersity index, p, for the micelles is

calculated from the Gaussian distribution of the micellar corona, m, which defines the relative
width of the micellar surface at the micelle solvent interface.
factor is given by 181
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178,179

In case of vesicles, the form

𝑑𝛴
𝜙 3𝑉𝑐𝑜𝑟𝑒 Δρ𝑠ℎ𝑒𝑙𝑙 𝑗1 (𝑄𝑅𝑐𝑜𝑟𝑒 ) 3𝑉𝑡𝑜𝑡 Δρ𝑠ℎ𝑒𝑙𝑙 𝑗1 (𝑄𝑅𝑡𝑜𝑡 )
(𝑄) =
[
+
]
𝑑𝛺
𝑉𝑠ℎ𝑒𝑙𝑙
𝑄𝑅𝑐𝑜𝑟𝑒
𝑄𝑅𝑡𝑜𝑡

(3)

where 𝑉core , 𝑉shell , and 𝑉tot are the core, shell and the total volumes, respectively. The shell
thickness is given by 𝑅tot − 𝑅core , with 𝑅core , the radius of the core and 𝑅tot , the outer radius of
the shell. Here the X-ray scattering length densities of the core and the solvent are identical
whereas, 𝑗1 is the spherical Bessel function, 𝑗1 (𝑄𝑅tot ) = (sin(𝑄𝑅tot ) − (𝑄𝑅tot ) cos(𝑄𝑅tot ))/
(𝑄𝑅tot )2. The polydispersity is modeled following the size distribution from TEM, which are
compatible with Gaussian and log-normal distribution functions. 182

Figure 10. SAXS data for different PLA-PAMAM macromolecules normalized by their volume
fraction ϕ. The data are modeled (solid lines) using core–shell sphere, core–shell cylinder (eq. 2)
and vesicle form factors (eq. 3) as described in the text.
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Figure 10 represents the scattering intensity normalized by their volume fraction, ϕ. The data
modeling was performed based on the TEM images. LDBCs 70-L-G3, 50-L-G3, 70-DL-G3, and
50-L-G3, the TEM images depict vesicle-like spherical structures in Figure 9.
The corresponding SAXS data were modeled using vesicle form factor as described in eq. 3.
In the case of 70-LG3, from TEM images although some wormlike arrangements of vesicles are
observed, the spherical vesicle structure is statistically more dominant from the scattering
measurements. The high Q scaling behavior of ~ Q−4, further supports the scattering from a smooth
surface. LDBCs 30-DL-G3 and 30-L-G3 TEM images depict spherical micellar structures. The
shell thickness (Rtot − Rcore) for the vesicles in 70-L-G3 and 50-L-G3 and DL-G3 systems
represents the membrane thickness.
Table 3. Sample size direct from dissolution method: Radius of the core Rcore, and the total radius
RtotSAXS, radius of the macromolecule from TEM, RTEM, hydrodynamic radius, RhDLS, from
DLS (intensity and number averaged distribution), and polydispersity, PD. All samples at volume
fraction, ϕ = 0.1%.
LDBCs
70-L-G3
50-L-G3
30-L-G3
70-DL-G3
50-DL-G3
30-DL-G3

SAXS
model
coreshell
vesicle
coreshell
vesicle
coreshell
micelle
coreshell
vesicle
coreshell
vesicle
coreshell
micelle

𝐑 𝐜𝐨𝐫𝐞SAXS
(nm)

𝐑 𝐭𝐨𝐭SAXS
(nm)

PDSAXS
(%)

𝐑 𝐓𝐄𝐌
(nm)

PDTEM
(%)

𝐑 𝐡 DLSa
(nm)

PDDLS
a
(%)

2.80.01

10.20.2

30

10.40.
1

241

61.235,
25.33

48, 26

1.40.01

7.30.3

25

6.10.1

231

12.14,
9.51

28, 20

0.80.01

7.20.1

20

7.10.1

302

7.81,
6.70.5

21, 28

1.70.10

8.60.3
NA

21

9.60.1

211

10.53,
7.60.3

31, 22

3.20.01

5.80.1

33

6.00.1

241

9.02,
5.81

30, 25

1.3 0.01

7.40.2

18

5.30.1

221

9.02,
5.81

25, 25
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The corresponding SAXS data were also modeled using a micellar form factor described in eq.
2. As shown by the scattering intensity, ~ Q−1.7, decay for real chains in good solvents, is a
characteristic feature of blob scattering from such micellar self-assemblies. 178,179 The results from
the SAXS data modeling are reported in Table 3. The increase in the scattering intensity at lowQ’s indicates the onset of aggregates, which is verified by DLS. The sizes, RtotSAXS and, RTEM,
from SAXS, and TEM in Table 3 are identical within the experimental uncertainties, whereas
RhDLS from DLS depends on the intensity and number averaged distribution. The discrepancy with
the results from DLS is attributed to the high polydispersity for 70-L-G3 in which various
aggregates were observed, yet accurate determination of the dimension of the cylinder from SAXS
and TEM was still achieved.

2.3 CONCLUSIONS
In this work, we have developed a feasible synthetic strategy to afford LDBCs that are composed
of PAMAM and PLA. These materials are made with a high percent conversion (83–94%)
indicating an ease in the synthetic route taken for a series of copolymers capable of self-assembly
at varying hydrophobic ratios. By only modifying the degree of polymerization of the hydrophobic
portion, we were able to obtain multiple morphologies and sizes from the same reaction
mechanism. Direct dissolution provides a facile and biocompatible methodology of nanoparticle
preparation for these copolymers, resulting in nanoparticles bearing positive surface charges.
Thermal analysis shows that the behavior of these LDBCs represents a combination of both
polymeric segments. The details of the morphology were elucidated by TEM and SAXS,
confirming these polymers exhibited selective self-assembly into the desired morphology of
vesicles and core-shell micelles.
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Advancing this study toward therapeutic drug delivery, reducing the surface charge will be
done to avoid impending cytotoxic effects while maintaining the potential of the nanostructure as
carriers. Within this scope, bilayer vesicles will be of particular interest due to their biomimetic
nature, which provides increased biocompatibility, while also serving as a dual-purpose drug
carrier for the simultaneous delivery of both hydrophobic and/or hydrophilic drugs. 183
In summary, the work discussed in Chapter 1 provides a suitable foundation for
understanding how the chemical make-up of the LDBC affects the overall self-assembled
structure. Ongoing research is aimed toward the assembly of interest, surface modification, and
exploitation of beneficial structural properties for future applications.

2.4 EXPERIMENTAL
2.4.1 MATERIALS AND METHODS
Reagents and solvents were purchased from commercial sources and used without further
purification unless otherwise specified. Tetrahydrofuran (THF) and dimethylformamide (DMF)
were degassed in 20 L drums and passed through two sequential purification columns (activated
alumina; molecular sieves for DMF) under a positive argon atmosphere. All synthetic procedures
were carried out under argon atmosphere using standard Schlenk line techniques unless otherwise
stated. 1,8-Diazabicyclo[5.4.0]undec- 7-ene (DBU) (98%, Acros) and chloroform (99.9%, Acros)
were distilled over CaH2. All lactide monomers (L and D, L) were recrystallized using toluene and
dried under high vacuum (−100 kPa). Macroinitiator (HO-G3Boc) used for ROP was freeze dried
before use. All the weighing for ROP was done in a glove box. Additional synthetic details, general
procedures, and tabulations of materials characterization can be found in Appendix A.
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2.4.2 GENERAL SYNTHESIS
The copolymers were synthesized using a “dendrimer first” approach

126

, in which the

dendritic segment acts as an initiator for ROP of the linear segment (Scheme 2). Briefly, the
PAMAM dendron was synthesized by a divergent method in which the growth of the dendron was
originated from a core functional group. Using ethanolamine as the focal point, a Michael addition
with methyl acrylate formed a half-generation dendron, followed by nucleophilic amidation with
ethylenediamine to afford full generation dendrimers. This was repeated up to generation 3 (G3).
The amine-terminated dendron was treated with di-tert-butyl dicarbonate in methanol to obtain
HO-G3Boc in 90% yield (Scheme 1.). The Janus-type LDBC intermediates (i.e., precursors LG3Boc and DL-G3Boc) were prepared by ROP of L-lactide or D, L-lactide employing DBU as
the catalyst. Variations in monomer feed gave the precursors in weight ratios of 90, 70, 50, and
30% with respect to PLA. The percentages indicate the weight ratio of the hydrophobic block with
respect to the total weight of the amphiphilic block copolymer. For example, if the system is 90%,
the hydrophobic polyester block contains the 90% of the mass of the block copolymer.
Removal of the Boc protecting group using trifluoroacetic acid (TFA) afforded the final
LDBC products L-G3 and DL-G3. Additional information regarding molecular weight
calculations and nomenclature for the resulting copolymers, as well as a detailed synthetic
procedure are presented in Appendix A.

2.4.3 CHARACTERIZATION OF BOC-PROTECTED INTERMEDIATES
1

H NMR spectra of PAMAM dendrons and Boc-protected precursors were performed on

a Bruker Avance spectrometer (Bruker,Germany), operating at 500 MHz with CDCl3 or MeODd4 as the solvent and TMS as an internal standard. The degree of polymerization of PLA was
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estimated by the integration values of the peaks corresponding to methylene protons as well as
Boc protons using 1H NMR. Molecular weight and PDI of the copolymers were determined by gel
permeation chromatography (GPC). All the measurements were done using either DMF or THF.
THF measurements were done at a flow rate of 1 mL/min at 35 ℃. A Shimadzu 20A GPC system
equipped with two Jordi Gel DVB500 columns and a differential refractive index detector was
used. Polystyrene standards (900–100,000 g/mol) were used for the calibrations curve and the data
were processed using a LCSolution ver.1.21 GPC option software. DMF measurements were done
at a flow rate of 0.3 mL/min at 50 ℃, on a GPC system equipped with Waters Alliance HPLC
System, 2695 Separation Module with 2 Tosoh TSKgel Super HM-M columns and Waters 2414
Differential Refractometer (RI) and Waters 2998 Photodiode Array Detector (PDA) was used.
Polystyrene standards (900–100,000 g/mol) were used for the calibrations curve and data were
processed using the Empower 3 software (Waters). An addition of the electrolytic salt, LiBr
(0.01%) was done to minimize effects such as polymer aggregation and/or adsorption associated
with the polymer or the columns, enabling normal fractionation to occur. 184–186
Matrix-assisted laser desorption time of flight mass spectrometry (MALDI-TOF MS) data
were acquired using a Bruker-Daltonics Autoflex III mass spectrometer with delayed extraction
using the reflector and positive ion mode. The samples were prepared by combination of polymer
analyte

(2

mg/mL)

in

THF,

trans-2-[3-(4-tert-butylphenyl)-2-methyl-2-propenylidene]

malononitrile (DCTB) (20 mg/mL) in THF as the matrix, and sodium trifluoroacetate (2 mg/mL)
in THF as the counter ion in a 15:15:1 ratio. MALDI-TOF MS data were calibrated against
SpheriCal dendritic calibrates from Polymer Factory (Stockholm, Sweden). Mn and Mw for all
polymers were calculated using the PolyTools software. Additional results of characterization are
presented in Appendix A.
40

2.4.3 PREPARATION AND CHARACTERIZATION OF SELF-ASSEMBLED AGGREGATES
Thermal analysis of the LDBCs was conducted using thermogravimetric analysis (TGA)
and differential scanning calorimetry (DSC). TGA measurements were performed on Seiko
Instruments TG/DTA 6200 (platinum pan, room temperature to 600 ℃, ramp rate of 20 ℃ min−1
under a nitrogen atmosphere) and analyzed using the MUSE Analysis software. DSC scans were
performed on TA Instruments DSCQ1000-0620 v9.9 (sealed aluminum pan, empty aluminum
reference pan, ramp rate of 20 ℃ min−1, two heating and cooling cycles) and analyzed using the
Universal Analysis 2000 4.4A software. The LDBCs having weight ratios of 70:30, 50:50, and
30:70 (in respect to PLA) were formed into aggregates employing a direct dissolution method.
Aggregates for LDBCs with ratios of 90:10 were formed using nanoprecipitation.
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2,72

For direct

dissolution, 1 mg of LDBC was added to a vial of MilliQ water (1 mL) while stirring followed by
sonication to achieve homogeneity. The nanoparticle suspensions were allowed to stabilize at room
temperature for 12 h. Nanoparticles formed via the nanoprecipitation method used acetone or THF
(according to the solubility properties of each system) as the organic solvent to dissolve 1 mg of
LDBC in a glass vial. The solution was added dropwise to a separate vial of MilliQ water (1 mL)
while stirring and sonication followed thereafter. Acetone/THF was allowed to evaporate under a
stream of nitrogen. Nanoparticles solutions were allowed to equilibrate for 12 h before testing.
Aggregate size and zeta potentials (ζ-potential) were determined by DLS. Measurements
were carried out on a Malvern Instrument Zetasizer Nano ZS using a He–Ne laser with a 633 nm
wavelength, a detector angle of 173 ℃ at 25 ℃ using a He–Ne laser with a 633 nm wavelength.
The vesicle concentration was 1 mg mL−1 and size measurements were performed three times on
each sample to ensure consistency. The morphological study of the aggregates formed from the
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LDBCs was carried out by TEM using a JEOL 1230 TEM was operated at 100 kV to collect the
TEM images using a Gatan Orius 831 bottom mounted CCD camera.
For critical aggregation concentration (CAC) measurements, pyrene (1.7 mg, 8.41 μmol)
was dissolved in 3.34 mL of acetone and 40 μL of the solution was added to 39.96 mL of deionized
water. A series of 12 concentrations of the nanoparticle suspension ranging from 10−8 mg L−1 to
1000 mg L−1 was prepared by dilutions of 1.8 mL per sample. A 1.8 mL of the pyrene solution
was added to each vial, and these solutions were equilibrated for 48 h in the absence of direct light.
The fluorescence spectra were obtained on a Varian Cary fluorescence spectrometer from Agilent
Technologies. An emission wavelength of 390 nm was used for pyrene and the excitation spectra
were recorded from 300 to 360 nm. The ratio of emission intensities at 338 and 333 nm was
graphed as a function of the log of the concentration. The CAC was determined as the
concentration at the intercept of the lines for the two linear regions of the obtained graphs
(Appendix A).
Small angle X-ray scattering (SAXS) was performed at the Advanced Photon Source at 9ID-C beamline, where Q = 4πsin(θ)/λ, for the scattering angle θ and X-ray wavelength λ = 0.59Å
at energy 21 keV. All data reduction into intensity I(Q) or, the macroscopic scattering cross-section
⃗ | was carried out following the standard procedures that are
d/d vs. momentum transfer 𝑄 = |𝑄
implemented in the Nika software package. 185 The solvent was subtracted as the background by
measuring water separately.

42

CHAPTER Ⅲ: SELF-ASSEMBLING PCL−PAMAM LINEAR DENDRITIC BLOCK
COPOLYMERS (LDBCS) FOR BIOIMAGING AND PHOTOTHERAPEUTIC
APPLICATIONS
This chapter adapted from Chandrasiri, I.; Abebe, D. G.; Loku Yaddehige, M.; Williams,
J. S. D.; Zia, M. F.; Dorris, A.; Barker, A.; Simms, B. L.; Parker, A.; Vinjamuri, B. P.; Le, N.;
Gayton, J. N.; Chougule, M. B.; Hammer, N. I.; Flynt, A.; Delcamp, J. H.; Watkins, D. L. SelfAssembling PCL–PAMAM Linear Dendritic Block Copolymers (LDBCs) for Bioimaging and
Phototherapeutic

Applications.
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This project is a collaborative work between Dr. Delcamp, J. H., Dr. Flynt, A., Dr.
Hammer, N. I., and Dr. Chougule, M. B. The synthesis and characterization of LDBCs were
performed by Chandrasiri, I. Synthesis and characterization of macroinitiator were done by Loku
Yaddehige, M. Synthesis and characterization of C5 was done by Gayton, J. N. Excited state
lifetime measurements were performed by Dorris, A. Cellular uptake, cytotoxicity, and
photothermal studies were done by Zia, M. F.

ABSTRACT
This study represents a successful approach toward employing polycaprolactone−
polyamidoamine (PCL−PAMAM) linear dendritic block copolymer (LDBC) nanoparticles as
small-molecule carriers in NIR imaging and photothermal therapy. A feasible and robust synthetic
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strategy was used to synthesize a library of amphiphilic LDBCs with well-controlled
hydrophobic to-hydrophilic weight ratios. Systems with a hydrophobic weight ratio higher than
70% formed nanoparticles in aqueous media, which show hydrodynamic diameters of 51.6 and
96.4 nm. These nanoparticles exhibited loading efficiencies up to 21% for a hydrophobic molecule
and 64% for a hydrophilic molecule. Furthermore, successful cellular uptake was observed via
trafficking into endosomal and lysosomal compartments with an encapsulated NIR theranostic
agent (C3) without inducing cell death. A preliminary photothermal assessment resulted in cell
death after treating the cells with encapsulated C3 and exposing them to NIR light. The results of
this work confirm the potential of these polymeric materials as promising candidates in theranostic
nanomedicine.
3.1 INTRODUCTION
With the work discussed in Chapter 2, a simple yet high yielding synthetic strategy was
developed to afford a library of LDBCs that are composed of PAMAM and PLA. The
nanoaggregates formed by these LDBCs exhibited favorable morphologies and sizes that can be
strategically employed in EPR mediated therapeutic delivery. This work provides evidence for the
potential of LDBCs as delivery vehicles in theranostic nanomedicine. Theranostics is a blend of
the terms therapeutics and diagnostics. This involves the combination of utilizing an imaging agent
to identify (diagnose) the disease and a drug as the therapeutic agent to treat the disease (therapy).
This work summarizes a successful effort taken to explore the potential applications of LDBC
nanocarriers in theranostic nanomedicine (Fig. 11).
A library of 50, 70, and 90 (i.e., weight percentage concerning PCL) LDBCs were
synthesized, and their compositions were confirmed. Nanoparticles were then formed in aqueous

44

media by nanoprecipitation, and the resulting structures were studied by dynamic light scattering
(DLS) and transmission electron microscopy (TEM). As a proof of concept study in theranostics,
the capacity of the nanoparticles (NPs) to encapsulate hydrophobic or hydrophilic molecules was
demonstrated. Potential uses in photothermal therapy were studied using a hydrophobic indolizine
cyanine dye (C3).187 Finally, the cytotoxicity of C3-loaded nanoparticles was evaluated with
human embryonic kidney (HEK) and Drosophila (S2) cells by lactate dehydrogenase (LDH) assay.

Figure 11. Graphical representation of PCL-G3 LDBCs forming vesicles in water by
nanoprecipitation while encapsulating a hydrophobic imaging/ photothermal agent.
3.2 RESULTS AND DISCUSSION
3.2.1 DESIGN AND SYNTHESIS OF PCL−PAMAM LDBCS
Herein is aimed to explore the potential applications of LDBC systems based on PAMAM and
polyesters. Molecular architecture design and selection of the polymer types for each block were
made with a focus on potential end uses as a biomaterial. Often referred to as the “artificial protein”
because of its biomimetic characteristics,141 a G3 PAMAM dendron was used as the hydrophilic
segment (similar to Chapter 2) due to its highly branched architecture that offers unique interfacial
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and functional performance. Furthermore, the dendrimer interior can be designed and modified to
facilitate the encapsulation of a vast array of guest molecules via noncovalent interactions (i.e.,
hydrogen-bonding, ligand, or acid−base interactions).188 For the hydrophobic segment, PCL was
used. PCL-containing (as a primary component) materials have been accepted by the Food and
Drug Administration (FDA) for use in surgeries, which provides evidence of safe practice in
humans. PCL exhibits a high permeability to drugs and has a lower acidic degradation rate than
other aliphatic polyesters.189 The low Tg (−60 °C) of PCL and its exceptional rheological properties
make it an appropriate candidate for various applications in the biomedical field.

Scheme 3. General synthetic route to LDBCs, PCL-G3; an example of 90:10 (90-PCL-G3) LDBC
obtained by ROP of ε-caprolactone monomer initiated by a PAMAM-G3-Boc macroinitiator (1)
yield PCL-G3-Boc (2), which is then deprotected to afford the final amphiphilic PCL-G3 LDBC
(3).
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The general synthesis of PCL-G3 is depicted in Scheme 3. Previous work has been reported
on the synthesis of LDBCs via copper (Cu) click chemistry approaches. However, these
approaches have limitations due to involving multistep syntheses to achieve different weight ratios
of the blocks. Such protocols require excess addition of one reactant to achieve high yields and
demand additional purification steps to remove the excess reactants from the reaction
mixture.190,191 Here, we took an approach that uses Boc-protected PAMAM (G3) containing a
hydroxyl focal point to initiate the ROP of ε-caprolactone with Sn(Oct)2 catalyst. By changing the
monomer feed ratio, a library of PCL-G3-Boc LDBCs were synthesized with mass ratios of 90:10,
70:30, and 50:50 PCL to PAMAM.
The heavy metal-containing catalyst concentration should be kept at the minimum possible
level to avoid potential toxicity-related issues in biological systems. Therefore, polymerization
kinetic studies were carried out to identify the minimum catalyst concentration (Figs. 63−65,
Appendix B). We observed that the LDBC systems, which have PAMAM > 30 wt % (i.e., 70PCLG3 and 50-PCL-G3), required higher catalyst loading than the 90-PCL-G3 system. This may
be due to the deactivation of the catalyst via coordination between the metal center and the
PAMAM dendron. Additional polymerization kinetic studies are provided in Appendix B (Fig. 65,
Appendix B). Catalyst equivalents of 0.3−0.6 (i.e., 0.3 for 90-PCL-G3 and 0.6 for 70-PCL-G3
and 50- PCL-G3) per hydroxyl focal point were used with the LDBC systems studied here.
As shown in Figure 12, an overlay of 1H NMR spectra displays characteristic resonance
peaks corresponding to the Boc-protected macroinitiator (2.19−3.69 ppm; Fig. 12a) and PCL (1.38,
1.64, 2.30, 4.05 ppm; Figure 12b,c) in CDCl3 (Figs. 59−62, Appendix B). Peaks representing both
blocks are shown in the spectrum of the LDBC intermediate before the Boc deprotection (Fig.
12b).
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Figure 12. 1H NMR overlay of the (a) macroinitiator (PAMAM-G3-Boc), (b) LDBC intermediate
(70-PCL-G3Boc), and (c) LDBC after Boc deprotection (70-PCL-G3) in CDCl3.
After the Boc deprotection, a drastic reduction in the intensity of the resonance peaks
corresponding to PAMAM is observed, yet signals corresponding to PCL remained visible. The
suppression of PAMAM signals is presumably due to a change in relaxation time that is caused by
a phase change. Note that deprotected PAMAM exhibits a decrease in solubility when placed in
an organic solvent. This insolubility leads to a solvent-driven nanoaggregation that helps to shield
the hydrophilic PAMAM from the organic solvent resulting in a reverse-phase nanoaggregation,
where PCL is the outer shell and PAMAM is the inner core. Upon the formation of these reverse
nanoparticles, PAMAM experiences a phase change from the solution phase to the aggregation
phase. This phase change can be considered as the reason for the change in the relaxation time for
the PAMAM protons as it is frozen or locked in the core of the nanoparticle. Similar behavior was
observed with previously reported amphiphilic LDBCs.151,192
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3.2.2 MOLECULAR WEIGHT ANALYSIS OF LDBCS
The molar mass and DP of the Boc-protected intermediates were calculated using 1H NMR
spectroscopy. The characteristic PAMAM resonance signal at 3.30 ppm (with 46 protons) was
used as the reference peak, and the PCL peak (methylene protons) at 4.05 ppm was integrated with
respect to PAMAM to calculate the DP. Molar mass calculations from 1H NMR were supported
by the GPC data, which are given in Table 4. Since evidence of reverse aggregate formation from
the LDBCs in less polar organic solvents is observed, the Boc-protected intermediates were
analyzed due to the 1H NMR signals appearing in a more molecular form. GPC chromatograms
are included in Appendix B (Fig. 66, Appendix B).
Table 4. Molecular weight characterization of PCL−PAMAM LDBCs of varying weight ratios by
GPC (chromatograms are shown in Appendix B Fig. 66).
1

H NMR

GPC

Systema

Mth

DPth

M w/
g mol-1

DP

Mn/
g mol-1

M w/
g mol-1

Ð

90-PCL-G3Boc

17465

132

18211

138

10185

15902

1.56

70-PCL-G3Boc

6350

34

6564

34

5548

8850

1.59

50-PCL-G3Boc

4127

15

3944

13

3702

5733

1.56

3.2.3 THERMAL ANALYSIS
Thermal analysis was achieved via TGA and DSC using deprotected LDBCs. In this
regard, all LDBCs of study possess NH3+ end groups, unless otherwise noted. TGA is a wellknown method for assessing polymer backbone and architectural structure.193 The polymeric
composition can be deduced by the qualitative characterization of the degradation process shown
by the weight loss percentage (ΔW) and the inflection point temperature (Td).194 All of the
measurements were taken under nitrogen conditions at a heating rate of 10 °C/min and are shown
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in Appendix B (Figs. 67 and 68, Appendix B). Two significant transitions in the slopes of the
degradation curves were observed for all of the LDBCs. Each slope change corresponds to the
decompositions of the phase-separated PAMAM and PCL blocks. The Td and ΔW data (Table 5)
suggest that the first degradation step is due to the PAMAM block and the second to the PCL
block. For example, in 70-PCL-G3 (70 wt % PCL) (Figure 13), two weight loss steps, the former
of 28% and the latter of 65%, were observed, which correlate to a theoretical weight ratio of 30:70
(PAMAM/PCL). Similar results were obtained with the other two systems (Table 5 and Figs. 67
and 68, Appendix B). These correlations between the weight ratio of the blocks, Td, and the weight
loss percentage after each degradation step provide qualitative evidence for the reliability of the
synthetic methodology employed.
Table 5. Thermal analysis data (TGA) confirming the weight ratios for each LDBCa.

System

a

1st step

Composition

2nd step

PAMAM

PCL

Td
(°C)

ΔW
(wt%)

Td (°C)

ΔW
(wt%)

90-PCL-G3

10

90

214

9

379

88

70-PCL-G3

30

70

216

28

312

65

50-PCL-G3

50

50

215

45

288

40

Td, inflection point temperature; and ΔW, weight loss percentage.
With the synthetic strategy established, the weight of the hydrophilic PAMAM portion was

kept constant, and the weight of the hydrophobic PCL portion was changed accordingly to obtain
the desired wt % ratios. The same trend can be seen when comparing the Td values at two thermal
steps. The first step corresponds to the decomposition of PAMAM and shows a minimal change
in Td values between different systems (only 1 °C fluctuation). The second step corresponds to the
decomposition of PCL and shows a significant decrease of Td between the LDBCs when
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decreasing the PCL weight ratio (Table 5). 90-PCL-G3, which has the highest weight ratio of PCL,
shows the largest Td (379 °C) when compared to 70 and 50-PCL-G3 with Td values of 312 and
288 °C, respectively. This trend suggests that the molecular architecture of the LDBCs has the
same PAMAM block but different PCL chain lengths.

Figure 13. TGA (green) and derivative thermogravimetry (DTG) (black) thermograms for 70PCL-G3 under nitrogen. (The arrow indicates the midpoint between the two major thermal
events.).
DSC thermograms showed a peak at 54 °C for 90-PCL-G3, which is hypothesized to be
the melting temperature (Tm) of PCL in the LDBC as the reported melting point range for pure
linear PCL is 59−64 °C, and the Tg of PCL homopolymer is −60 °C (Fig. 69, Appendix B).195
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3.2.4 SELF-ASSEMBLY AND MORPHOLOGY
The self-assembly into nanoparticles of the LDBCs in water was done using the
nanoprecipitation method.198 The sizes and morphologies were studied using DLS (Appendix B
Table 13) and TEM (Figs. 14 and 72 and 73, Appendix B). The intensity-average DLS size
distribution shows that the 90-PCL-G3 LDBC forms aggregates of approximately 96.4 nm in
hydrodynamic diameter (Dh), while the Z-average size shows a diameter of 77.8 nm, which
indicates the presence of a smaller particle distribution as well. Cryo-TEM images (Fig. 14)
confirm the presence of two significant distributions of spherical particles with an average
diameter of 71.1 nm, which correlates with the Z-average diameter observed from DLS. Although
it is not evident from the cryo-TEM images herein, previous studies have shown that LDBCs
having hydrophobic (polyester) wt % >70% form bilayer vesicles.55,192,199 Uranyl formate was
used as a contrasting agent to improve the visibility of the PCL bilayer. The contrasting agent
accumulates more in the dense polyester bilayer, and this can be seen as a darker region in the
room-temperature TEM image (Fig. 72, Appendix B). Using these lighter and darker regions of
the TEM image, indirect evidence can be obtained about layered vesicle morphologies.177

Figure 13. Nanoparticles formed by (a) 90-PCL-G3, (b) 70-PCL-G3, and (c) 50-PCL-G3 under
cryo-TEM, 1% uranyl formate as the contrast agent. Additional analysis is included in Appendix
B (Figs. 72 and 73, Appendix B).
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Aggregates formed from 70-PCL-G3 LDBCs exhibited high polydispersity with an
average Dh of 45.6 nm and a PDI of 0.50. Size distribution by intensity shows a polymodal
distribution with two significant sizes of 51.6 and 359.4 nm, which result from the secondary
aggregation of regular nanoparticles. This hypothesis was supported by TEM images, which show
two major size distributions of spherical shaped particles with average diameters of 48.1 and 29.8
nm. Additional secondary clusters made of smaller particles correspond well with the polymodal
distribution observed in DLS (Fig. 73, Appendix B). Furthermore, additional TEM images with a
contrast agent suggest vesicle morphologies for these spherical shaped particles formed by 90PCL-G3 and 70-PCL-G3 LDBC systems (Fig. 72, Appendix B).
In comparison with 90 and 70, 50-PCL-G3 also showed a high polydispersity of 0.53 and
a polymodal distribution in the DLS intensity plot, where the major distribution showed a Dh of
221.4 nm and a minor distribution of 16.7 nm. The majority of the particles were seen as clusters
in the TEM images, which explains the high polydispersity and larger size DLS distributions.
Isolated particles from the clusters showed a spherical shape with an average diameter of 14.0 nm
and were assumed to be core−shell micelles because the PCL bilayer was not visible in the TEM
images (Fig. 73b, Appendix B). The morphological evidence obtained from the TEM analysis was
further supported by encapsulation studies described below.
When considering the sizes of the individual particles (isolated particles form clusters), a
decreasing trend was observed, and more aggregation of the particles into clusters was shown. We
hypothesize that the smaller particles (70-PCLG3 and 50-PCL-G3) tend to form larger aggregates
to decrease the relative surface energy, while the LDBC solution that has larger particles (90-PCLG3) shows minimum secondary aggregation. It is well established that there is an inverse
proportional relationship between the diameter of the spherical nanoparticles and the relative
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surface energy.200,201 This postulation can be further supported by the Brownian agglomeration
mechanism. In this case, the formation of larger aggregates results from particles colliding and
fusing as a result of their random motion.202 For this study, temperature (the main factor affecting
Brownian motion), sample volume, and material concentration were kept constant among all of
the trials. Therefore, the smaller particles should have higher kinetic energy than the larger
particles and thus gain higher velocities. This leads to a higher collision rate of the particles and
makes more aggregates/clusters in the systems that have smaller nanoparticles. 202
The observed morphologies follow previously reported and established morphological
trends, which can be explained using the packing of the copolymer chains and molecular
curvature.52,53,55,199,203 The packing parameter (p), established by Israelachvili et al. and defined in
Eq 2, combines copolymer properties to predict the curvature and the prepared
morphologies.52,54,203 In Eq 2, v is the volume of the hydrophobic chains, ao is the optimal area of
the head group (hydrophilic PAMAM block in our case), and Lc is the hydrophobic chain length.
According to the theories of self-assembly, p should be less than 1/3 to form spherical micelles
and between 1/2 and 1 to form vesicles/polymersomes.51,53,204 For these LDBCs, ao remains
constant because the hydrophilic block is the same for all systems. Therefore, p is defined by the
weight ratio of the hydrophobic block. When the weight ratio of the hydrophobic block is ≥70%,
the higher volume and length lead to the formation of vesicle-like structures. Spherical micelle
structures obtained from 50-PCL-G3 can also be explained similarly.

𝑝=

𝑣
𝑎0 𝐿𝑐

(2)
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Surface charges (ζ-potential) of the nanoparticles ranged from 37.0 to 72.4 mV. The lowest
ζ-potential value was obtained for the 90-PCL-G3 system, which showed the highest
monodispersity and did not have larger secondary aggregates. For the other two LDBC systems
that had larger secondary aggregates, higher surface charges were observed (Table 13). This trend
can be explained from the ζ-potential distribution plots of each system, where 90-PCL-G3 shows
a monomodal and a narrow distribution that correlates with the PDI observed from DLS.
Nevertheless, for 70-PCL-G3 and 50-PCL-G3, bimodal/polymodal distributions are observed with
peaks corresponding to higher surface charges, which are assumed to be from the larger secondary
aggregates (Figs. 77−79, Appendix B). Such values are viewed as highly stable in colloidal
research, and those of 20−30 mV are prevalent in the drug delivery literature.162,183 In general,
positively charged nanoparticles can easily penetrate cell membranes since they are commonly
known to be negative.123,166 Since the high ζ-potentials for the LDBC nanoparticles are concerning,
in vitro cytotoxicity studies were undertaken. These studies (vide infra) show that the cell death
induced by these polymeric nanoparticles is ≤15% at the highest concentrations, which provides a
preliminary indication that these materials are nontoxic to biological systems.
The CAC for the LDBCs ranges from 0.67 to 6.16 mg/L as determined by a fluorescent
probe (pyrene), which provides further evidence of stable nanoparticles. DLS analysis shows a
nonlinear relationship between LDBC concentration and scattering intensity, confirming the
presence of nanoscale vesicles/micelles above the CAC (Fig. 80, Appendix B). The CAC varied
among the LDBC systems, with an observed dependence on hydrophobic wt %. The CAC is one
of the basic parameters that defines the thermodynamic stability of a nanoparticle. Lower CAC
values indicate higher thermodynamic stability. When the polymer chains have a higher number
of points of interaction, higher thermodynamic stability is gained and leads to lower CAC
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values.159 Lower CAC values were exhibited by LDBCs, which have longer PCL chains. The
CAC for 90-PCL-G3 (0.67 mg/L) was the lowest (10-fold lower than 50-PCL-G3, 6.2 mg/L) due
to its increased hydrophobic interactions among the longer PCL chains.116,205 The values for 70PCL-G3 and 90-PCL-G3 (Fig. 80, Appendix B) are analogous to those found in the literature and
correlate to their potential as exceptional biomaterials.206,207
3.2.5 ENCAPSULATION STUDIES
As the goal of this work is to evaluate the potential of these nanoparticles as carriers in
therapeutic delivery and/or theranostics, the ability to uptake hydrophobic or hydrophilic
molecules was studied. As a hydrophobic drug model, curcumin, chemically referred to as
diferuloylmethane (Fig. 81, Appendix B), was selected. This is a highly hydrophobic small
molecule that exhibits antioxidant, anti-inflammatory, and anticancer properties.208,209 Because
aggregates formed from 90-PCL-G3 and 70-PCL-G3 show evidence of bilayer vesicle formation
in an aqueous medium, we hypothesized that these LDBCs would improve the water solubility of
curcumin via the encapsulation into the PCL bilayer of the vesicle. Figure 15 validates the
solubilizing abilities of the LDBCs (Fig. 15a) and enhanced drug-applicable curcumin loaded in
all three LDBC systems (Figure 15b−d).

Figure 14. (a) Left, a dispersion of curcumin in H2O; and right, curcumin-loaded 90-PCL-G3, (b)
magnified image of curcumin loaded 90-PCL-G3, (c) curcumin-loaded 70-PCL-G3, and (d)
curcumin-loaded 50-PCL-G3. (Curcumin and the LDBC concentrations were kept at 0.5 and 1.0
mg/mL, respectively, for all of the systems).
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In the absence of 90-PCL-G3, curcumin is entirely insoluble. Figure 15a (left) shows where
precipitated curcumin is visible at the bottom of the tube and adheres to the sample vial as a
separate layer on the water surface. In contrast, the encapsulation of curcumin in 90-PCL-G3
nanoparticles (Figure 15a, right) provides a homogeneous and transparent yellow-orange solution.
As shown in Figure 15b,c, LDBCs containing hydrophobic portions at ≥70 wt % increased the
solubility of curcumin by giving clear homogeneous solutions, while 50-PCL-G3 system exhibits
a highly turbid solution with sedimentation on the bottom of the vial (Fig. 15d). The presence of
longer hydrophobic chains results in a significantly higher EE% and DL% of curcumin (Table 14).
This observation correlates with the morphological differences observed in TEM analysis.
Nanoparticles showing the evidence of bilayer vesicle morphologies (70-PCL-G3 and 90-PCLG3) encapsulated more curcumin and increased its solubility. Furthermore, 90-PCL-G3 showed
an enhanced DL% and EE% toward curcumin than 70-PCL-G3, suggesting that the higher
hydrophobic wt % LDBCs more efficiently load hydrophobic molecules. Encapsulation of
curcumin in the hydrophobic bilayer of the 90-PCL-G3 particles leads to an increase in Dh from
96.4 to 255.5 nm as determined with DLS, suggesting an expansion of the particles upon
encapsulation of curcumin. Another possibility for this size expansion is secondary aggregate
formation upon the encapsulation. However, the monomodal size distribution and 0.10 PDI in DLS
suggest that 90-PCL-G3 particles, upon loading, formed no secondary aggregates (Figs. 74 and
75, Appendix B). DLS analysis of before and after encapsulation with 70-PCL-G3 shows a size
increase consistent with secondary aggregation from 359.4 to 550.5 nm after the encapsulation,
which is an indication of smaller aggregates forming larger secondary aggregates. 210,211 In contrast
with 90-PCL-G3, isolated vesicles (first distribution in DLS; Fig. 75, Appendix B) of 70-PCL-G3
did not show a significant increase in size (only a 4 nm increase of Dh), which was expected due
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to its relatively low loading efficiency (Table 14). The DL% of 50-PCL-G3 is insignificant at ≤1%
due to its shorter hydrophobic chain and smaller particle size. Furthermore, there was no increase
in particle size after curcumin encapsulation. It is interesting to note that the 90-PCL-G3 can uptake
the hydrophobic drug (curcumin) up to 21.7 DL% without making secondary aggregates while
keeping the PDI at 0.10, which is a positive indication of its potential to be utilized in therapeutic
delivery applications.
Rhodamine-B (RhB) (Fig. 81, Appendix B), an amphoteric dye and fluorochrome, was
used to evaluate the uptake of hydrophilic molecules. Both 90-PCL-G3 and 70-PCL-G3 systems
showed high DL% for RhB. There are three possible sites where hydrophilic molecules can be
loaded into the vesicles of 90-PCL-G3 and 70-PCL-G3 LDBC systems: (1) the water pocket that
is trapped in the vesicle, (2) the inner PAMAM layers, and (3) the outer PAMAM layers (Fig. 11).
50-PCL-G3 has a lower DL%, which can be explained by the lack of both the water pocket and
the inner PAMAM layer because of the micelle morphology and the smaller particle size. This
observation provides indirect evidence for the morphologies deduced from TEM analysis. When
comparing the 90-PCL-G3 and 70-PCL-G3 systems, both have the same DL% values even though
the particles of 70-PCL-G3 are smaller in size before the encapsulation. Interestingly, the 70-PCLG3 particle size has expanded and reached the same size as the 90-PCL-G3 system after dye
encapsulation, which explains the similar encapsulation behavior of both systems. In addition, a
decrease in surface charge (down to a range between 24.2 and 39.6 mV) was observed for all three
systems after the encapsulation of RhB, which can be an added advantage in potential therapeutic
delivery applications. This observation is yet to be explained, and experiments with different
hydrophilic molecules and computational modeling are actively being carried out.
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3.2.6 BENCHMARK STUDIES WITH CYANINE-BASED PHOTOTHERMAL IMAGING
AGENT C3
The preliminary encapsulation studies with curcumin and RhB provide substantial
evidence of the ability of the LDBCs to uptake both hydrophobic and hydrophilic molecules
separately. Aiming to apply the LDBC materials toward theranostics, we sought to increase the
solubility of a hydrophobic photothermal/imaging agent and study the cellular uptake and toxicity
of the agent-loaded LDBCs. Recently, the reported near-infrared (NIR) emissive cyanine dye C3
was selected for these studies.187 Cyanine-based dyes are commonly used as imaging agents for
photoacoustic (PAI) and near-infrared fluorescence (NIRF) imaging. They are capable of
transforming absorbed NIR photons to heat as a photothermal (PT) agent and to lower energy NIR
photons for an image-guided combinatorial phototherapeutic agent. However, several bottlenecks
limit the application of cyanine dyes, such as solubility and instability in aqueous media, which
decrease their imaging and therapeutic potential.212–214
As a benchmark for the application of LDBCs in photothermal therapy, hydrophobic
cyanine dye C3 (Fig. 81, Appendix B) was encapsulated in the 90-PCL-G3 and 70-PCL-G3
systems. The dye is not soluble in water, but encapsulation in LDBCs increased its solubility
dramatically (Figs. 16a,16c) to afford DL% values of 4.3% for 90-PCL-G3 and 1.7% for 70- PCLG3. As the dye is insoluble in water, absorption, emission, and the lifetime of the free dye were
evaluated in a mixture of ACN/H2O (1:1) and compared with the encapsulated dye in water.
Nonencapsulated C3 has a low-energy absorbance maximum wavelength (λmaxabs) and emission
wavelength maxima (λmaxemis) of 696 and 728 nm, respectively (Figs. 16 and 81, Appendix B).
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C3-loaded nanoparticles show only modest shifts of λmaxabs and λmaxemis with values of 693 and 720
nm, respectively, in water.

Figure 15. Top: dispersion of C3 in (a) water, (b) 70-PCL-G3 in water (by nanoprecipitation), and
(c) C3 encapsulated in 70-PCL-G3 LDBC nanoparticles in water. Bottom: vis−NIR emission
overlay of the dye in 1:1 ACN/H2O (yellow) and encapsulated nanoparticles in water (blue) with
excitation at 650 nm. (C3 and the LDBC concentrations were kept at 0.5 and 1.0 mg/mL,
respectively, for all of the systems).
However, the absorption profile of the dye does change significantly with a dramatic
broadening of the absorption curve from a half-peak height width of ∼80 nm to a half-peak height
width of ∼200 nm upon encapsulation. Additionally, the higher-energy vibronic shoulder shifts
from approximately 25% of the λmaxabs peak height to approximately 80% of the λmaxabs peak height
upon encapsulation. This broadening and vibronic shoulder increase in intensity are indicative of
cyanine-type dye aggregation, as can commonly be observed from neat films or at interfaces.215,216
Notably, the emission curve shape did not change in a similarly dramatic way relative to the
absorption curve shape upon encapsulation. The quantum yields for nonencapsulated and
encapsulated C3 were measured to be less than 1%. Such values are not uncommon for cyanine
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dyes in water with exceptionally popular dyes such as indocyanine green, which is FDA approved
and has been used routinely in surgical/diagnostic settings for multiple decades.217 Furthermore,
the lifetime (τ) of the excited state was evaluated before and after encapsulation (Fig. 82, Appendix
B). The kinetic trace for the nonencapsulated C3 solution was fit using a single-exponential decay
function and gave a lifetime of 10.24 ps. The C3 LDBC system was fit using a double exponential
with a short component of τ = 11.47 ps and a longer component of τ = 106.51 ps. The double
exponential nature of the encapsulated C3 suggests either the presence of both the free dye and its
encapsulated form during measurements or a dynamic process occurring upon photoexcitation.
Given the dramatically longer lifetime of C3 when encapsulated, the nanoparticles are capable of
inducing an extended excited-state lifetime of an encapsulated dye. This is most likely due to an
increased delocalization of the excited state due to C3 molecular aggregation occurring inside of
the nanoparticle.218
The storage lifetime of the delivery system (carrier of the therapeutic agent) is a crucial
factor in biomedical applications. For the LDBC nanoparticles, the change in the PDI and the size
of the nanoparticles (with no C3 loading) were insignificant after 10 days (Fig. 83, Appendix B),
and no visual variances (i.e., no color change or precipitate) were observed. This indicates that the
nanoparticles, without any dye loading, are stable in an aqueous media for up to a minimum of 10
days. Upon C3 encapsulation (loading with the dye), an increase in PDI (increase by 0.037 for 70PCL-G3 and 0.184 for 90-PCLG3) and a change in particle size (<10 nm) were observed. Similar
changes in particle size and dispersity upon loading have been observed.116,219,220 After the
encapsulation of C3, the PDI remained without a significant change for 5 days, but a 0.03 increase
in PDI was observed between the fifth and seventh days of testing. The particle sizes remained
within a normal distribution between 53.2 and 63.8 nm for 7 days (Fig. 83, Appendix B). In
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addition, we monitored the percentage of the encapsulated dye remaining in the nanoparticles in
12−24 h intervals using UV−vis−NIR absorbance spectroscopy. LDBC nanoparticles were able to
hold approximately 80% of the encapsulated dye after 5 days. Almost a 50% drop of absorbance
intensity was observed between the 5th and 10th days, which shows that the majority of the loaded
dye is released after 5 days. The combined results from the DLS and absorbance spectroscopy
indicate that the C3-encapsulated nanoparticles are stable up to 5 days after the preparation.
Without specific preservation techniques such as PEGylation or lyophilization, the observed
storage lifetimes are impressive and quite comparable to similar liposome-like nanoparticles that
have undergone cargo loading.48,221
3.2.7 IN VITRO CYTOTOXICITY
The cytotoxicity of empty and C3-loaded nanoparticles was tested in HEK and S2 cell
lines. HEK cells were selected as a representation of human cell interactions, and S2 fruit fly cells
were selected to represent nonhuman animal cell interactions (Figs. 17 and 84, Appendix B). After
treatment with 90-PCL-G3 and 70-PCL-G3 formulations without C3, the cell viability was above
90 and 85% at the highest concentration (500 nM) for HEK cells and S2 cells, respectively (Figs.
17 and 84, Appendix B; Table 15), which suggest a general nontoxicity for both copolymers.
Noticeably, however, there is a lower cell survival rate of S2 cells at lower concentrations of
LDBCs. This can be explained by the properties of the cell: S2 cells have been described as
macrophage-like cells; thus, they exhibit higher and more efficient uptake properties relative to
HEK cells.222,223 As a result, higher toxicity is observed for the S2 cells due to a more efficient
uptake of free polymer.
There was no significant increase in cell death with C3-loaded nanoparticles at the same
conditions, with the exception of 90-PCL-G3 loaded with C3 introduced to the cell environment
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in the highest concentration studied at 500 nM, where a modest reduction of cell viability of 17%
is observed (Fig. 17 and Table 15, Appendix B). This could be a consequence of some instability
in vivo for this particular formulation or LDBC (i.e., higher hydrophobicity content than 70-PCLG3) that results in a release of C3 or precipitation of the polymer aggregates, which perturbs
cellular processes.224 Together, these results indicate that the encapsulation of the selected
imaging/photothermal agent does not induce significant cytotoxicity at varied concentrations
(Figs. 17a,17b). As a potential cell imaging and phototherapeutic agent, cellular internalization
was evaluated by measuring fluorescence signals generated by C3-loaded nanoparticles within S2
and HEK cells via confocal microscopy (Figs. 17 and 84, Appendix B). Additionally, LysoTracker
(green) was used to visualize lysosomes and to assess the intercellular trafficking of cells after
treatment with dye-loaded nanoparticles (Figs. 17c,17d).225,226 When overlapping the emission of
LysoTracker and the encapsulated NIR agent (Figs. 17c,d,c′,d′), both fluorescence signals are
observed from the same regions of the cells with overlap coefficients of 0.74 and 0.85 for 90-PCLG3 and 70-PCL-G3 loaded with C3, respectively. Fluorescent signals associated with C3 could be
observed in HEK cytoplasmic bodies, which partly overlap with lysosomal signals. This suggests
a model where polymers interact electrostatically with cellular membranes, followed by an
entrance into endosomes through routine internalization of membranes. Once in the
endomembrane system, the nanoparticles become trafficked, in part, to lysosomes. Similar
observations are made when analogous studies were conducted with S2 cells with overlap
coefficients of 0.61 and 0.74 for 90-PCL-G3 and 70-PCL-G3 loaded with C3, respectively (Fig.
84, Appendix B). The uptaken nanoparticles seen by the assay provide supporting evidence
confirming the low toxicity of the LDBC materials with the loaded imaging/photothermal agent.
Such observations act as indirect evidence that dye-loaded nanoparticles are accumulated in
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lysosomes affording visualization of the cellular compartment. As the polymers are designed from
biodegradable components, degradation of the nanocarrier is expected to occur inside the
lysosomes after imaging with low toxicity. Further work is needed to study the biological
degradation of these materials and planned as a follow-up study to this work.

Figure 16. Cell viability after treatment with 90-PCL-G3 (a) and 70-PCL-G3 (b). Cytotoxicity
(percentage) was determined by the LDH assay. Error bars denote the standard error, while letter
denotes significance groups as determined by Tukey HSD (p ≤ 0.05). HEK cells after exposure to
dye-loaded nanoparticles (c, c′, 90-PCL-G3; and d, d′, 70-PCL-G3) and LysoTracker green. The
left panels (c, d) are a merge of the bright field with LysoTracker (green) and C3 (red) with overlap
coefficients of 0.74 and 0.85, respectively, which shows colocalization between C3 fluorescence
and LysoTracker. The right panels (c′, d′) are the C3 dye fluorescence alone and (c″, d″) are the
LysoTracker fluorescence panels (scale bar = 25 μm).
Given the high molar absorptivity and emissive quantum yield, C3 is expected to be a good
photothermal therapy dye.216 The preliminary phototherapeutic efficacy of C3-loaded
nanoparticles was evaluated in vitro. To assess the photothermal capacity, a series of C3-loaded
nanoparticles with different concentrations were irradiated (633 nm), and the temperature change
was monitored (Fig. 85, Appendix B). The photothermal measurements were conducted as the
temperature change of a bulk solvent using a temperature probe in a dilute solution of the material.
Results indicate a less than 5 °C increase in temperature relative to a control sample (empty PCL-
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G3 nanoparticles). Figure 18 summarizes the metabolic activities of the HEK cells treated with
C3-loaded nanoparticles with and without NIR exposure.

Figure 17. C3-loaded nanoparticles of (a) 90-PCL-G3 and (b) 70-PCL-G3, respectively, with HEK
cells shown before (green) laser exposure and after (red) exposure. (c) Control with no nanoparticle
loading (scale bar = 200 μm). (d) Cell death count before and after laser exposure with and without
nanoparticles.
HEK cells treated with C3-loaded nanoparticles of 90-PCL-G3 and 70-PCL-G3 (500 nM)
and irradiated with NIR light for 8 min showed appreciable cell death. Results of the in vitro
photothermal assay indicate that for both 90-PCL-G3- and 70-PCL-G3 C3- loaded nanoparticles,
an increase in cell death is achieved after laser exposure when compared to cells treated with laser
irradiation alone. Figs. 18a,18b shows an increased number of dead cells marked by red
fluorescence after laser exposure, while Figure 18c demonstrates a statistically significant differ
ence in the number of dead cells before and after irradiation. The results yield promising evidence
of utilizing C3-loaded nanoparticles, where PCL−PAMAM LDBCs act as carriers for
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photothermal and imaging applications. While the observed photothermal activity displays
promise, additional studies are needed to afford a highly efficient photothermal dye and polymer
construct.227,228
3.3 CONCLUSIONS
Amphiphilic PCL−PAMAM LDBCs are attractive for the development of potential
therapeutic delivery systems to be utilized in nanomedicine. A feasible and robust synthetic
strategy was employed to construct a series of LDBCs by changing the chain length of the
hydrophobic segment. In addition to the conventional structural characterization with NMR and
GPC, thermal analysis provided qualitative evidence for the reliability of the synthetic strategy.
According to the variations in hydrophilic-to-hydrophobic weight ratios, we observed various
morphologies for their nanoparticles in water. Evidence of polymersomes (bilayer vesicles mimics
of biological vesicles) was observed for LDBCs above 70% hydrophobic (PCL) wt %, and these
materials have the potential to be used as biocompatible carriers in nanomedicine. The CAC
studies provide further evidence for the stability of the nanoparticles.88 The CAC values for 70PCL-G3 and 90-PCL-G3 are similar to those reported in the literature and correlate well to the
capacity of the copolymers as efficient biomaterials.229–231 Preliminary studies showed that the
LDBC nanoparticles can uptake a hydrophobic therapeutic agent up to 21.7 DL% without
destabilizing the nanoparticle. Furthermore, high loading (63% DL) efficiencies toward RhB
indicate that these nanoparticles can be employed to deliver either hydrophilic or hydrophilic
therapeutic agents.
Aiming to apply the material toward theranostics, we were able to increase the solubility
of a hydrophobic photothermal/imaging agent, C3, by loading it into LDBC as nanoparticles.
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These dye-loaded nanoparticles were successfully uptaken by HEK and S2 cells without inducing
significant cell death. Even though the nanoparticles show positive surface charges, demonstrating
minimal cell toxicity provides evidence for the biocompatibility of the nanocarriers. We were able
to induce cell death by exposing the C3 dye (loaded into cells via encapsulation in nanoparticles)
to a NIR laser. Photothermal studies of cell death after treatment with C3-loaded nanoparticles and
upon laser exposure support a significant cell death relative to control samples that were not
exposed. This is a positive and firm indication of the potential of these materials as nanocarriers
in nanomedicine. Ongoing research is aimed toward the assembly of interesting LDBCs, utilization
of different photothermal and imaging agents to achieve enhanced imaging and photothermal
efficiencies, and understanding of nanoparticle stability via structural and surface modifications.
3.4 EXPERIMENTAL
3.4.1 MATERIALS AND METHODS
Common solvents and reagents were purchased from commercial suppliers and used as
received without additional purification. Tetrahydrofuran (THF) and N,N-dimethylformamide
(DMF) were purified using a solvent purification system. PAMAM-G3-Boc and C3 were prepared
as previously reported.187,232 All of the synthetic procedures were conducted under an ultra purified
nitrogen atmosphere using standard organic synthesis techniques (e.g., Schlenk line) unless
otherwise specified. Chloroform (99.9%, Acros), chlorobenzene (99.8%, Sigma-Aldrich), and εcaprolactone (99%, BTC) were distilled over CaH2. Tin(II) 2-ethylhexanoate (Sn(Oct)2,
92.5−100%, Sigma-Aldrich) was dried under high vacuum (−100 kPa) for 5 days before use. The
macroinitiator (PAMAM-G3-Boc) used for ring-opening polymerization (ROP) was freeze-dried
prior to use. All starting materials used for the ROP were weighed in a glovebox. 1H(13C) NMR
spectra were collected on a 300 or a 400 MHz spectrometer [Bruker Avance spectrometers
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(Bruker, Germany)]. Chemical shifts (δ) are denoted in parts per million (ppm) relative to an
internal standard (tetramethylsilane, TMS) and referenced to a protonated solvent obtained from
Cambridge Isotope Laboratories, Inc. (CDCl3: δH 7.26 ppm, δC 77.16 ppm; MeOD: δH 3.31, 4.87
ppm, DMSO-d6: δH 2.50 ppm, δC 39.52 ppm). Abbreviations used are s (singlet), d (doublet), t
(triplet), q (quartet), m (multiplet), and/or b (broad). A JEOL 1230 TEM was used at 100 kV to
obtain electron microscopy images using a bottom-mounted charge-coupled device (CCD) camera
(Gatan Orius 831). Samples were prepared 1 day in advance and then filtered and diluted within 1
h of the experiment. For the room-temperature TEM, carbon-coated, 300 mesh grids were plasmacleaned just before applying the sample solution. Negative staining was carried out immediately,
followed by applying a 1% uranyl formate solution to the grid. For the cryo-TEM, grid freezing
was achieved by using a Mark IV Vitrobot (FEI Co., Hillsboro, OH). Blotting parameters were
optimized for each sample: usually, two, 1-s blots with a force of 0, +1, or +2 or alternately one,
2-s blot with a force of 0 or −3. Prepped grids were kept in liquid nitrogen until moved to a 626
Single Tilt (Gatan Inc., Pleasanton, CA) cryo transfer holder. Grids were imaged via a JEOL 1230
TEM, using a 100 kV accelerating voltage. Images were captured with a CCD camera (Gatan 831
Orius) and analyzed using the Digital Micrograph software. Tissue culture cells were grown under
standard conditions. HEK293 cells were cultured in standard Dulbecco’s modified Eagle’s
medium (DMEM) media containing 10% fetal bovine serum (FBS) and antibiotics (e.g.,
penicillin/streptomycin) under a 37 °C CO2-injected incubator. Drosophila S2 cells were kept in
Schneider media containing antibiotics (e.g., penicillin/streptomycin) and 10% FBS. S2 cells were
grown at 26 °C.
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3.4.2 GENERAL SYNTHESIS
As outlined in Scheme 3, a generation 3 PAMAM dendron with a hydroxyl focal point
(PAMAM-G3-Boc) was utilized as the macroinitiator for the ROP of ε-caprolactone to synthesize
the linear segment of the block copolymer. The PAMAM dendron was synthesized according to a
previously reported procedure in which ethanolamine acted as the focal point.232 To preserve the
hydroxyl focal point as the principal nucleophile, the terminal amine groups were protected with
di-tert-butyl decarbonate (Boc).232 Boc-protected LDBC intermediates (i.e., before making the
dendritic portion hydrophilic) were made by the ROP of ε-caprolactone, employing Sn(Oct)2 as
the catalyst. Different weight ratios of the LDBC intermediates with respect to PCL (i.e., 90, 70,
and 50%) were obtained by varying the feed ratio for the lactone monomer. In regard to the total
weight of the amphiphilic (Boc deprotected) block copolymer, note that the percentages denote
the weight ratio with respect to the hydrophobic segment. As an example, when an LDBC is
labeled as 90%, the nomenclature indicates that the hydrophobic polymer segment (PCL) contains
90% of the weight of the block copolymer: 90-PCL-G3. Amine Boc protection was removed using
trifluoroacetic acid (TFA) to make the dendritic portion hydrophilic and obtain amphiphilic LDBC
systems (abbreviated as PCL-G3 in the main text).

3.4.3 CHARACTERIZATION OF BOC-PROTECTED INTERMEDIATES
Proton NMR spectra of all intermediates (PAMAM dendrons and Bocprotected) were
collected using a Bruker Avance spectrometer (Bruker, Germany) operating at 400 or 300 MHz.
Either MeOD, DMSO-d6, or CDCl3 was used as the solvent with TMS as an internal standard. The
degree of polymerization (DP) of PCL was calculated by 1H NMR. The molecular weight and the
polydispersity index (PDI) of each LDBC intermediate were obtained via gel permeation
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chromatography (GPC) using DMF as the mobile phase. GPC measurements were carried out on
a Waters Alliance HPLC System at 50 °C at a flow rate of 0.3 mL/min using a 2695 Separation
Module equipped with 2 Tosoh Bioscience columns (TSKgel Super HM-M), a Waters 2414 DRI,
and a Waters 2998 Photodiode Array Detector (PDA). The data was evaluated using Waters
Empower 3 software. The GPC system was calibrated using polystyrene standards.

3.4.4 PREPARATION AND CHARACTERIZATION OF SELF-ASSEMBLED AGGREGATES
Thermogravimetric analysis (TGA) and differential scanning calorimetry (DSC) analysis
were employed to evaluate the thermal stability of the LDBCs. For each sample, a platinum pan
was used, and the thermal studies were conducted under a nitrogen atmosphere at temperatures
ranging from 25 to 400 °C at a ramp rate of 15 °C/min. The results were analyzed using the MUSE
Analysis software. A TA Instruments DSCQ1000-0620 v9.9 was used to collect DSC scans at
ramp rates of 20 °C/min with three heating/cooling cycles. The data was analyzed using TA
Instruments software, Universal Analysis 2000 4.4A.
The LDBCs possessing weight ratios of 90:10, 70:30, and 50:50 (with reference to PCL)
were formed into nanoparticles by employing nanoprecipitation.233 Using a glass vial, THF (200
μL) was added as the organic solvent to dissolve 1 mg of LDBC. The resulting solution was added
(dropwise) to a second vial containing MilliQ water (1 mL) while gently stirring and sonicating.
THF was removed by allowing it to evaporate under constant airflow. Formulations were allowed
to equilibrate for 12 h before testing.
Nanoparticle size and zeta potential (ζ-potential) measurements were conducted on a
Zetasizer Nano ZS (Malvern Instrument) using a He−Ne laser (633 nm) detector angle of 173° at
25 °C. The nanoparticle concentration was 1 mg/mL, and all measurements were done in triplicate
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to ensure consistency. The morphological study of the aggregates formed from the LDBCs was
carried out by environmental TEM and cryo-TEM. CAC measurements were acquired via
fluorescence spectroscopy and DLS. The fluorescence probe method was carried out according to
a previously reported procedure.15 A series of eight concentrations ranging from 10−8 to 10−1 mg/L
were used for the experiment. The fluorescence spectra were collected on a Varian Cary
fluorescence spectrometer (Agilent Technologies). For the DLS method, the same concentration
series was prepared, and the measurements were taken at 25 °C. The measurements were repeated
three times to assure reproducibility. By plotting the intensity of scattered light as a function of
polymer concentration (mg/L), the CAC was determined.
3.4.5 ENCAPSULATION STUDIES
Rhodamine-B (RhB), curcumin, and indolizine cyanine (C3) dye 187 were separately loaded
into nanoparticles. Chemical structures and absorbance profiles for each dye are included in
Appendix B. The encapsulation efficiency (EE%) and dye loading efficiency (DL%) were
determined for each molecular species. For curcumin-loaded vesicles/micelles, curcumin (1 mg)
and block copolymer (2 mg) were dissolved in THF (200 μL) and added dropwise to MilliQ water
(2 mL) while stirring and sonicating. THF was removed by allowing it to evaporate under a stream
of nitrogen. Formulations were allowed to equilibrate for 12 h, and the unloaded dye was filtered
out using a 0.45 μm syringe filter. Then, water was removed by freeze-drying, and the dye-loaded
nanoparticles were redissolved in THF (5 mL). The curcumin concentration was estimated by
(𝑀𝑐)

𝐷𝐿 (%) = 100 × (𝑀𝑝+𝑀𝑐)
(𝑀𝑐)

𝐸𝐸 (%) = 100 × (𝑀𝑐𝑖)

(4)

(5)
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using a Cary 6000 UV−visible spectrophotometer at 423 nm based on the standard calibration
curve obtained from free curcumin in THF. A similar procedure was followed for C3 dye (1 mg),
and UV−visible measurements were taken at 705 nm. DL% and EE% were calculated using the
following formula.
with MC = mass of curcumin or C3 in the nanoparticle, MP = mass of LDBC, and MCi = mass of
curcumin or C3 initially added during nanoprecipitation.116
For RhB encapsulation, RhB (10 mg) was dissolved in MilliQ water (2 mL) in a vial, and
the polymer (2 mg) was dissolved in THF (200 μL) in a separate vial. The polymer solution was
added into the RhB solution dropwise while sonicating and stirring. The resulting mixture was
dialyzed with a 3.5 kD dialysis bag in water until all of the untrapped dye escaped, as determined
by testing the outer solution using a UV−vis spectroscopy at 554 nm until no dye was detected.
The amount of unloaded dye was calculated via a UV−vis data analysis with a standard calibration
curve. Then, the encapsulated dye amount was calculated by subtracting the unloaded dye amount
from the initial weight. DL% and EE% were calculated using the same formula (Eq. 4, 5) used for
the curcumin studies.

3.4.6 OPTICAL ACTIVITY OF C3-ENCAPSULATED NANOPARTICLES
Excited-state lifetimes were obtained from femtosecond transient absorption spectroscopy
(fsTAS) measurements for both C3 and C3-encapsulated. The fsTAS measurements were
performed using a femtosecond transient absorption spectrometer (Ultrafast Systems Helios Fire)
and a Ti:sapphire regenerative amplified laser system (Coherent Astrella). Both samples were
placed in a 2 mm cuvette and excited by a 695 nm beam generated by pumping an OPerA Solo
optical parametric amplifier (Coherent) with the 800 nm fundamental output of the fs amplifier.
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Kinetic traces were obtained by plotting the ΔA at 480 nm for both samples over time, where the
transient of both the encapsulated and nonencapsulated samples strongly absorbed. Absolute
quantum yields for both samples were obtained with a Horiba Quantamaster 8075-21
spectrofluorometer and an integrating sphere. A xenon lamp monochromated to 695 nm served as
the excitation source.

3.4.7 STORAGE STABILITY OF C3-ENCAPSULATED NANOPARTICLES
The storage stability of C3-encapsulated nanoparticles was evaluated by means of both
dynamic light scattering (DLS) and absorbance spectroscopy. For the DLS method, C3 (1 mg) and
LDBC (2 mg) dissolved in THF (200 μL) were added dropwise to MilliQ water (2 mL) while
stirring and sonicating. THF was removed by allowing it to evaporate under a stream of nitrogen.
Formulations were permitted to equilibrate for 12 h, and the unloaded dye was filtered (removed)
using a 0.45 μm syringe filter. Particle size and the PDI were measured in 24 h intervals over 5
days and then 48 h intervals up to 10 days. Measurements were carried out on a Zetasizer Nano
ZS (Malvern Instrument) using a He−Ne laser (633 nm) having a detector angle of 173° at 25 °C.
To evaluate the stability of the formulations, the percent change in the size and PDI was plotted
against the number of days.
For the UV−vis method, the samples were prepared using the same procedure mentioned
in the DLS method. Absorption intensities were obtained using a Cary 600 UV−visible
spectrophotometer in 24 h intervals for 5 days and then 48 h intervals up to 10 days. To assess the
stability of the formulations, the percent decrease in the maximum intensity (λmax) was plotted
against the number of days.
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3.4.8 IN VITRO CELL UPTAKE AND CYTOTOXICITY ASSAY
Following self-assembly, C3-encapsulated nanoparticles were added to tissue culture
media. HEK293 cells were grown under standard conditions (37 °C, 5% CO2) in DMEM media
with 10% FBS. S2 cell cultures were preserved in S2 media with 10% FBS at 25 °C. Distribution
of dyes following the uptake was visualized with a laser scanning confocal microscope (Zeiss LSM
510 META) following a 24 h incubation with the nanoparticles. Cells were co-stained with a
LysoTracker Green DND-26 (Invitrogen) to simultaneously image lysosomes. Cytotoxicity of the
nanoparticles was then determined with a CyQUANT LDH Cytotoxicity Assay Kit (Invitrogen)
using a microplate reader (BioTek Synergy H1). Differences in viability between loaded and
unloaded particles at different concentrations were determined by a Tukey honestly significant
difference (HSD) test.

3.4.9 IN VITRO CELL UPTAKE AND CYTOTOXICITY ASSAY
In Vitro Photothermal Assay. HEK cells near 100% confluency were treated with 500 ng
of polymers and incubated overnight in 5% CO2 at 37 °C. A 633 nm laser (5 mW) was used to
irradiate cells for 8 min, followed by incubation for 2 h. Afterward, cell death was assessed with a
LIVE/DEAD Cell Imaging KitTM Invitrogen following the manufacturer’s protocols. Confocal
microscopy was then used to assess cell death through fluorescence (568 nm excitation, >580 nm
emission) of propidium iodide accumulation in cell nuclei (red channel). The number of dead cells
was counted in three biological replicates. A one-tailed t-test was used to assess the statistical
significance between loaded and unloaded nanoparticles.
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CHAPTER Ⅳ: CORE CROSS-LINKED PCL-PAMAM LINEAR DENDRITIC BLOCK
COPOLYMERS (LDBC) FOR THERANOSTIC NANOMEDICINE

4.1 INTRODUCTION
Nanoparticles formed from amphiphilic linear-dendritic block copolymers (LDBCs) have
demonstrated their potential as promising candidates for a variety of applications in nanomedicine
(Chapter 2, Chapter 3). Specifically, polymersomes (bilayer vesicles) formed by LDBCs exhibit
superior properties relative to other nanoformulations owing to their biomimetic morphologies,
favorable sizes for EPR mediated delivery and enhanced stability. However, conventional noncrosslinked polymersomes tend to disintegrate before reaching the disease site due to systemic
dilution, temperature, ionic strength, and pH value in blood. In addition, interactions (adsorption)
between the bloodstream components (plasma proteins) and the polymersomes’ building blocks
(unimers) leads to premature release of the therapeutic agents and suboptimal therapeutic
responses.14,67
Crosslinking is known to be simple and straightforward, yet a reliable method to minimize
premature disintegration, thereby assures enhanced circulation times and sustained release of the
therapeutic agents.14,234 Formation of the crosslinks can be done either in the core or the corona of
the nanoparticle. The typical driving force for self-assembly is hydrophobic interactions, but in
crosslinked nanoparticles, there are additional attractive forces between unimers. These added
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interactions improve the mechanical stability of the nanoparticles and keep them intact upon a
higher degree of dilution. There are two main approaches to crosslinking concerning the bonding
type: covalent (chemical) crosslinking and noncovalent (physical) crosslinking. Even though the
covalent crosslinking can introduce more stability to the system, applications have been limited
due to the excessive synthetic steps, inability to self-repair after being disintegrated or damaged
(before reaching the target site), and weak responsiveness towards external stimuli.
Noncovalent crosslinking has drawn more attention from an application perspective
because it introduces self-repair properties to the nanoparticle and does not involve excessive
synthetic steps, thus providing better synthetic accessibility.20,116,234,235 Noncovalent crosslinking
can be categorized according to the crosslinking mechanism, including H-bonding, pi-pi stacking,
dipole-dipole interactions, hydrophobic interactions, and coordination complexing.

These

noncovalent interactions form multiple bonds among unimers and stabilize the nanoparticle while
preserving the reversible and dynamic nature that facilitates self-healing.104,236

Figure 18. Graphical representation of PhPCL-G3 LDBCs forming vesicles in water by
nanoprecipitation while forming core-crosslinks by pi – pi interactions.
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Herein is reported a practical approach to enhance the stability and hydrophobic therapeutic
loading efficiency of PCL-PAMAM LDBC nanocarriers by core crosslinking. Pendant phenyl (Ph)
groups were introduced to the PCL chains to generates pi-pi interactions among PCL chains in the
hydrophobic bilayer (Fig. 19). Based on previous research in amphiphilic block copolymer selfassembly, an LDBC system consisted of 70% hydrophobic wt% was selected for the study. 53,192,232
By introducing different weight ratios of Ph substituents (5%, 10%, and 20% concerning the
hydrophobic wt%), a library of Ph substituted LDBCs ware synthesized. After confirmation of the
compositions, core crosslinked polymeric nanoparticles were formed in aqueous media by
nanoprecipitation. The nanoparticles were then characterized by dynamic light scattering (DLS)
and transmission electron microscopy (TEM) for the sizes and morphologies. Critical aggregation
concertation (CAC) and hydrophobic loading efficiencies were calculated and compared with a
similar but non-crosslinked system. Finally, in-vitro photothermal activities were evaluated with
selected hydrophobic photothermal agents [C5, Indocyanine green (ICG)].
4.2 RESULTS AND DISCUSSION
4.2.1 DESIGN RATIONALE
The purpose of this work is to increase the stability and hydrophobic therapeutic loading
efficiency of PCL-PAMAM LDBC nanoparticles (structure, Fig. 83, Appendix B). The potential
of these nanoparticles to be utilized in photothermal therapy and NIR imaging has been proven
recently (Chapter 3).192,232 The linear dendritic structure and the selection of polymer types (i.e.,
PCL and PAMAM) focuses on the end-use of these nanoparticles as carriers in nanomedicine.
PCL (hydrophobic block) is known for its excellent biocompatibility, thus approved by the Food
and Drug Administration (FDA) for safe practice in humans (e.g., surgical material containing
PCL as a primary component).

In contrast with other biocompatible polyesters, such as
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polylactides, PCL demonstrates an increased permeability towards hydrophobic therapeutic
agents. The glass transition temperature for PCL is comparatively low (-60 ℃), which adds a
softer rubbery nature to the polymer matrix. Furthermore, its lower acid degradation rate comes as
an added advantage when designing nanocarriers for slow release applications.189,195,237,238 In
addition to its biocompatibility, PAMAM provides unique surface functionalities that can be
strategically modified to achieve target specific and stimuli-responsive carriers. Owing to the
highly branched architecture, dendrimers have internal cavities with high volume that facilitate the
transportation of a range of guest molecules via guest-host interactions.
The synthetic approach was designed to introduce pendant phenyl (Ph) groups to the liner
PCL chain of the LDBC. We modified one of our previously reported synthesis to achieve a
reasonable synthetic strategy for this work (Scheme 4). A Boc protected G3 PAMAM dendron
with an OH focal point (1) was used as the macroinitiator for the ROP of a mixture of ɛcaprolactone and Ph-ɛCL. The Ph-ɛCL monomer was synthesized by the Baeyer-Villiger oxidation
of 4-phenyl cyclohexanone (Scheme 5, Appendix C). Previous work has been reported on
introducing benzyl and phenyl substitutions to PCL chains as a post-modification via alpha
alkylation and click-chemistry ((CuAAC and thiol-ene).239,240 However, these approaches have
setbacks due to the use of extreme reaction conditions (e.g., strong bases such as LDA), excessive
synthetic and purification steps, and lack of synthetic feasibility to control the substituent amount.
Furthermore, click approaches demand the addition of one reactant in excess to achieve good
yields and require added steps to remove the excess reactants.135,191
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Scheme 3. General synthetic route to PhPCL-G3 LDBCs; obtained by ROP of ɛ-Caprolactone
(blue) and Ph-ɛCL (purple) monomers initiated by PAMAM-G3-Boc macroinitiator (1) to yield
PhPCL-G3Boc (LDBC precursor) (2), which is then deprotected to obtain the final amphiphilic
PhPCL-G3 LDBC (3)

To overcome these challenges and control the substituent amount through a one-step
synthesis, the caprolactone monomer was modified to achieve Ph-ɛCL prior to the ROP. By simply
changing the ɛ-caprolactone to Ph-ɛCL feed ratio, we introduced different weight ratios (5%, 10%,
and 20%) of pendant phenyl groups through a one-step and one-pot synthesis. This synthetic
strategy provides the simultaneous control of the phenyl substituent amount and the hydrophobic
to hydrophilic weight ratios of the LDBC. The hydrophobic to hydrophilic weight percent (wt%)
of the LDBC was kept constant (i.e., 70:30, PCL/PhPCL: PAMAM) regardless of the PhPCL wt%.
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Although Sn(Oct)2 catalyst is known for its biocompatibility,241 the catalyst concentration
was kept at a minimum to avoid possible toxicity towards biological systems. Catalyst equivalents
of 0.6 per hydroxyl focal point were identified as the optimal amount for 70-PCL-G3 (system with
no Ph substituents) and remained the same for the Ph-PCL series.232 The percent conversion shown
for the polymerization of 5-PhPCL and 10-PhPCL systems were above 93%. However, the 20PhPCL system did not reach completion with the same catalyst amount (0.6 eq). The NMR
spectrum (Fig. 85, Appendix C) shows that the polymerization was terminated after adding the
required number of Ph-ɛCL units (i.e., 3) to the growing polymer chain. This indicates that the
increased addition of phenyl groups to the growing polymer causes a depletion of the catalytic
strength of Sn(Oct)2. When more pendant phenyl groups are added, several propagating chains can
form pi-pi interactions and form a bulky intermediate. This can disrupt the coordination among
the propagating terminal, Sn(Oct)2 catalyst, and the monomer that may result in chain growth

Figure 19. 1H NMR overlay of the (a) macroinitiator (PAMAM-G3-Boc), (b) LDBC precursor
(70-PCL-G3Boc), and (c) LDBC precursor (10-PhPCL-G3Boc) in CDCl3.
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termination. Therefore, we moved forward with 5-PhPCL and 10-PhPCL systems, and
polymerization kinetic studies are being carried out with the focus of understanding the catalyst
deactivation and termination of the chain growth under an increased Ph-εCL environment. The
NMR spectra overlay of PAMAM-G3Boc, 70-PCL-G3Boc, and 10-PhPCL-G3Boc (Fig. 20)
illustrates the characteristic signals along with the incorporation of the macroinitiator to the phenyl
substituted LDBC system. Resonance peaks corresponding to the Boc-protected macroinitiator
(2.19−3.69 ppm) and the LDBC with no phenyl substituents (70-PCL-G3Boc; 1.38, 1.64, 2.30,
4.05 ppm) are shown in Figs. 20a and 20b, respectively. Figure 20c represents the 10-PhPCLG3Boc,

the LDBC precursor with pendant phenyl substituents (10% of the hydrophobic weight) while
maintaining the overall 70:30 hydrophobic to hydrophilic weight ratio. After the Boc deprotection,
the intensities of PAMAM resonance peaks decreased dramatically (Fig. 85, Appendix C) in
CDCl3. This observation was expected, and similar results were observed with the previously
reported LDBC systems. The deprotection decreases the solubility of PAMAM in organic
solvents, which leads to solvent driven self-assembly. As the self-assembly occurs in an organic
solvent, more soluble PCL forms the outer corona of the nanoparticle while less soluble PAMAM
stays shielded in the core. This is described as reverse-phase nano aggregation. Due to phase
change experienced by the PAMAM in the nanoparticle, a change in relaxation time occurs. This
is assumed to be the reason for the suppression and baseline broadening of PAMAM peaks in the
NMR spectrum.
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4.2.2 MOLECULAR WEIGHT ANALYSIS OF LDBCS
Molar mass characterization was done using NMR spectroscopy and GPC. The analysis
was done with the Boc protected LDBC precursors because of their better solubility in organic
solvents. As the hydrophilic block (PAMAM-G3) remains constant for all the LDBC systems, the
characteristic peak at 3.30 ppm (with 46 protons) was used as the reference peak. The PCL peak
at 4.05 ppm (methylene protons) was integrated with respect to the PAMAM reference peak to
calculate the degree of polymerization of the hydrophobic chain. The number of pendant phenyl
groups was calculated using the aromatic resonance signals between 7.05 and 7.35 ppm (Fig. 20c).
Molar mass data obtained from GPC agrees with the calculated molar mass values from NMR
(Table 16). The calibrants used for the GPC calibration (PMMA) do not correlate perfectly with
the linear dendritic architecture; thus, deviations from a perfect Gaussian nature were observed in
GPC chromatograms (Fig. 86, Appendix C). Similar observations have been reported in studies
related to linear dendritic architecture.192,232 It is a known fact that intermolecular ester interchange
occurs at high temperatures. As the ROP was carried out at 130 ℃, this ester interchange is
possible until the most abundant molar mass distribution is established.193,242 This may lead to
broad molar mass distributions that result in a higher PDI. There are reported polyester copolymer
syntheses where the PDI went up to around 2 because of this reason.193 However, with the synthetic
approach taken in this work, PDI values did not exceed 1.3, which can be considered as a favorable
trend. NMR spectra and GPC chromatograms are given in Appendix C.

4.2.3 THERMAL ANALYSIS
Thermal properties of PhPCL-G3 LDBC systems were evaluated using TGA and DSC.
Boc deprotected amphiphilic LDBC systems (containing NH3+ end groups) were used for the
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analysis. TGA is a well-established and convenient method to deduce relative compositions of
block copolymers qualitatively.193 By analyzing the weight loss percentage (ΔW) and the
inflection point temperature (Td) related to each block, a qualitative calculation of decomposition
temperatures and the weight percent of the blocks was carried out.
As the polymers consist of three different components (PAMAM, PCL, and PhPCL), three
different thermal degradation events were expected. The thermogram of the 10-PhPCL-G3 system
(Fig. 21) showed concurrence with the theoretical assumption by giving inflection point
temperatures at 226, 321, and 422 ℃. The Td and ΔW values (Table 17) suggest that the first
degradation step corresponds to the hydrophilic block (PAMAM).232 The theoretical PAMAM
ratio in the block copolymer is 30%, which qualitatively aligns with the ΔW percentage obtained
for the first degradation step, 32.5% (Fig. 87, Appendix C). The latter decompositions sum up to
67.5 %, represents the hydrophobic block (PCLand PhPCL) that should contain 70% of the weight
theoretically. According to the inflection point temperatures reported in the literature, Td at 321 ℃
represents the decomposition of PCL. 232
Furthermore, the thermograms reported for the non-phenylated polymer that does not
contain PhPCL (70:30 PCL-PAMAM LDBC) did not show the decomposition at 422 ℃.232 This
suggests that the final thermal event is related to the decomposition of phenyl substituents on the
PCL chain (Fig. 21). For the 10-PhPCL-G3 system, PhPCL takes 10% of the hydrophobic weight.
That is 7% of the total weight of the block copolymer. ΔW percentage of the final thermal event
is approximately 8%, provides more evidence of the decomposition of pendant phenyl groups. The
correlations between the weight ratio of each block, composition, Td, and ΔW at each thermal
degradation event supports the reliability of the synthetic methodology developed for this work.
Similar observations were given by the 5-PhPCL-G3 system (Figs. 88, 89, Appendix C). However,
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the decomposition step for PhPCL units was not prominent enough to conduct a reliable
calculation. The lower PhPCL content in 5-PhPCL-G3 is the most probable reason for this
observation.

Figure 20. TGA (green) and derived thermogravimetry (DTG) (yellow) thermograms for 10PhPCL-G3 under nitrogen. Vertical dotted lines indicate Td for major thermal degradation events.
When comparing inflection point temperatures between the two LDBC systems (5 and 10PhPCL-G3), almost similar values (< 5 ℃) were observed for the degradation of PAMAM and
PCL decomposition (Table 17). As both systems were designed to preserve a 70:30 hydrophobic
to hydrophilic ratio, PAMAM dendron and the PCL chain length remain the same. This explains
similar trends observed in the decomposition temperatures for each polymer. Nonetheless, the
number of phenyl substituents are different in each LDBC system (2 for 10-PhPCL-G3 and 1 for
5-PhPCL-G3), resulting in a noticeable difference in the phenyl group decomposition step. The
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LDBC with a higher number of phenyl substituents exhibited a higher Td (422 ℃), while the LDBC
with a lower number of phenyl substituents showed a lower Td (410 ℃).
Broad peaks with low intensity were observed in DSC thermograms for both polymeric
systems (Figs. 90-91, Appendix C). For the LDBC systems that consist of a polyester block above
90 wt%, sharp and intense thermal events were reported in the literature. However, when the
hydrophobic wt % decreases, changes in the peak shape (from sharp and intense to broad) were
observed as the PAMAM block and the substituents (i.e., phenyl in this work) strongly affect the
thermal properties of PCL at lower PCL weight ratios. When more phenyl substituents are present,
higher deviations from the theoretical melting point was observed. The melting point range and Tg
for pure PCL were reported as 59−64 °C, and −60 °C, respectively. The melting peak for 5PhPCL-G3 appeared at 51.5 °C and 48.3 °C for 10-PhPCL-G3, demonstrating the influence of
substituents on the properties of homopolymer. Such deviations are well known for the block
copolymers and point to the contribution of substituents to the thermal properties of the polymeric
system.
4.2.4 CRITICAL AGGREGATION CONCENTRATION (CAC) AND SELF-ASSEMBLY
As stated in Chapter 1, the low stability of nanocarriers upon subjection to systemic
circulation is a significant bottleneck regarding the development of efficient nanoparticle-based
delivery systems. Many different factors govern the stability of the nanoaggregates, including
polymer concentration, the molar mass of the block responsible for the core-formation, and the
loaded host molecules.243 The polymer concentration is a crucial parameter when forming selfassemblies. The CAC denotes the minimum polymer concentration needed to form self-assembled
nanoaggregates in a particular medium. A dilution below the CAC leads the nanoaggregates to
disintegrate/disassembly rapidly.243,244 The magnitude of CAC primarily depends on the size and
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hydrophobicity of the hydrophobic block. Thereby increasing the molar mass and the
hydrophobicity of the hydrophobic block, the CAC can be decreased.245 However, increasing the
hydrophobic molar mass has limitations because the block copolymer should maintain a particular
hydrophobic : hydrophilic weight ratio to form biocompatible morphologies and sizes.56,229,232,243
Core-crosslinking is an approach to stabilize the nanoparticles without affecting the molar
masses of the blocks. There have been numerous reported instances where lower CACs were
achieved via crosslinking.20,200,239,246 Phenyl groups can stabilize the particle not only by making
the crosslinks but also by increasing the hydrophobicity of the core-forming block. The CAC for
5-PhPCL-G3 was 6.17 mg/L, which does not show a notable decrease concerning a system with
no phenyl groups (70-PCL-G3). In contrast, CAC for 10-PhPCL-G3 nanoparticles was 3.9 mg/L,
a 37.1 % relative decrease of the CAC obtained for 70-PCL-G3. This reflects the effect of core
crosslinking on the aggregation behavior of the nanoparticle. Nanoparticles with low CAC values
resist disintegration upon a more extensive dilution. Such systems can tolerate higher degree
dilution, such as bloodstream dilution, making those nanocarriers more stable in biological
systems. Furthermore, physical core-crosslinking can reform the particle even after a
disintegration, which is known as self-healing.104,236 CAC calculations are included in Appendix
C (Fig. 92, Appendix C).
As 5-PhPCL-G3 LDBC nanoparticles did not display significantly increased loading
efficiencies and decreased CAC values, the rest of the studies were carried out with 10-PhPCL-G3
LDBCs. For the size and morphological analysis, nanoaggregates were formed in water by
conventional nanoprecipitation. The size distributions and dispersity of the nanoaggregates in the
solution were determined using DLS. The Z-avg particle size was 74.44 nm, which was
represented by two major size distributions. According to the intensity average scattering plots,
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one distribution ranged around 130.6 nm and the other distribution around 18.3 nm. The existence
of these distributions was supported by number and volume average plots as well. The dispersity
of these nanoaggregates was 0.45, which is typical for a nanoparticle dispersion with several size
distributions.
When comparing these results with the size distributions of the non-phenylated system (70PCL-G3),232 an increase in particle size was observed. The phenyl substituents increase the
volume of the hydrophobic block that could lead to a volume expansion of the hydrophobic core,
thereby increasing the size of nanoparticles. Other than the major size distributions, larger
secondary aggregates (clusters formed by smaller nanoparticles) were observed for the 70-PCLG3 system. The formation of secondary aggregates results from the fusion of smaller nanoparticles
to reduce their excess surface energy.200–202,232 However, DLS plots for the 10-PhPCL-G3 system
did not show any evidence of secondary aggregates, which is a favorable trend (Fig. 93, Appendix
C). The probable reason for this observation is the reduced surface energy of the nanoparticles due
to the size expansion. Additional DLS data is included in Appendix C (Figs. 94-96, Appendix C).
According to the literature on LDBCs, hydrophobic weight ratios ≥ 70 wt% self-assembled
into bilayer vesicles (polymersomes).192,232 This can also be justified by the theories of selfassembly. Israelachvili et al. showed that morphologies and the curvature could be predicted using
the packing parameter (p) given in eq 1. Where v is the hydrophobic volume, ao is the optimal area
of the head (hydrophilic block), and Lc is the length of the hydrophobic block.

𝑝=

𝑣
𝑎0 𝐿𝑐

(1)

The hydrophilic area (a0) is not a variable for the LDBCs discussed in this work because a
G3 PAMAM dendron is a constant throughout the series. Therefore the hydrophobic block volume
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and the weight percentage is the driving force to achieve different curvatures that define p.
According to the theory, p should be between 1/2 and 1 to form vesicles. Therefore it is logical to
deduce that the spherical nanoparticles observed here possess vesicle-like (polymersome)
morphologies.

4.2.5 PRELIMINARY ENCAPSULATION STUDIES
In order to identify the optimal phenyl substituent percentage to enhance the hydrophobic
loading ability, the DL% of each LDBC system was compared with a similar LDBC with no phenyl
substituents. The studies were initiated with curcumin, a hydrophobic molecule (chemically
referred to as diferuloylmethane). The high hydrophobicity and the ease of detection (UV-Vis
spectroscopy) inherited from curcumin were employed to observe the changes in hydrophobic
loading profiles. As phenyl groups are present in the hydrophobic bilayer, we hypothesized that
the phenyl substituted LDBCs would increase the water solubility of curcumin via enhanced pi-pi
interactions. Both 5 and 10-PhPCL-G3 dramatically increased the water solubility of curcumin
(Figs. 22b,c). Without the presence of LDBC nanoparticles, the dye was completely insoluble in
water, forming a separate layer on the water surface and the vial walls (Fig. 22a). The reported
DL (%) for the LDBC system with no phenyl groups (70-PCL-G3) is 13.70 %.232 DL% of 5PhPCL-G3 nanoparticles towards the hydrophobic molecule was 13.73 %, which is not a
significant increase compared to the non-phenylated system (70-PCL-G3, DL% = 13.30%).
owever, the 10-PhPCL-G3 system showed DL % 17.50, which is a 27.7 % relative increase in the
loading efficiency towards a hydrophobic guest molecule.
The preliminary encapsulation studies with curcumin suggest that introducing 5 wt%
phenyl substituents is insufficient in significantly enhancing hydrophobic loading efficacy. On the
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other hand, increasing the substituent wt% up to 10% demonstrated a notable enhancement in the
loading efficiency. Similar results were observed with several other selected hydrophobic
molecules (Table 18, Appendix C).

Figure 22. (a) dispersion of curcumin in water (b) curcumin loaded 5-PhPCL-G3, (c) curcuminloaded 10-PhPCL-G3.
4.2.5 PHOTOTHERMAL EFFICIENCY
There have been reported attempts of utilizing cyanine-based photothermal imaging agents
to showcase the potential of LDBC nanocarriers.232 These dyes are known for their applications in
photoacoustic imaging (PAI) and near-infrared fluorescence (NIRF) imaging. Additionally, they
can convert absorbed NIR photons to heat, which makes them useful in photothermal therapy.
However, the hydrophobicity and instability in the aqueous medium have hindered their full
potential to be used as photothermal and imaging agents in biological systems.
Herein, we focus on enhancing the water solubility of selected hydrophobic cyanine dyes
and evaluate their potential in photothermal thermal therapy and NIR-imaging. Recently, the
reported near-infrared (NIR) emissive cyanine dye C5 was selected for these studies. 187 The dye
is not soluble in water, but encapsulation in LDBCs made it highly soluble in water. (Figure 23).
The DL % obtained for 10-PhPCL-G3 was 3.41%, which was 2.58 % for 70-PCL-G3 (no phenyl
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substituents). In this case, the phenyl substituted LDBC system has increased the loading
efficiency of the cyanine dye by 32.1 %.
The excited-state lifetime (τ) was evaluated before and after encapsulation (Fig. 99,
Appendix C). The free molecule in the solution (1:1 ACN, H2O) decays with a single exponential
and a lifetime of about 45.67 ps. The encapsulated molecule shows double exponential decay with
a fast component of around 1.36 ps and a slow component at 8.91 ps. These two components could
be a result of several different phenomena. The hydrophobic (PCL) bilayer is the most likely area
for the dye to accumulate in the nanoparticle. As PCL is semicrystalline in nature

247

, the

hydrophobic bilayer should have a semicrystalline arrangement; thus, the dye located in different
regions should have different aggregation natures.

Figure 21. (a) Dispersion of C5 in water (b) C5 loaded 10-PhPCL-G3 (c) photothermal activity of
PhPCL-G3 nanoparticles.
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Free (nonencapsulated) C5 in a solution of ACN and H2O (1:5) gave a low-energy
absorbance maximum wavelength (λmaxabs) and emission maxima (λmaxemis) of 810 and 829 nm,
respectively (Figs. 97, 98, Appendix C). C5 did not show significant peak shifts for absorption or
emission upon the encapsulation (Fig. 97, Appendix C). However, when comparing the low energy
absorption peak and higher-energy vibronic shoulder, a significant intensity increase was observed
for the higher-energy vibronic shoulder. This vibronic shoulder intensity increase is an indication
of the aggregated state of cyanine-type dyes.215,216 Similar observations can commonly be
observed from neat films or at interfaces.

187,215

The quantum yields (QY) measured for free (in

1:1 ACN, H2O) and encapsulated C5 were less than 1%. Such low QY values are expected for
cyanine type dyes in water as highly popular, and FDA approved dyes such as indocyanine green
(ICG) has shown comparable results.217
The excited-state lifetime (τ) was evaluated before and after encapsulation (Fig. 99,
Appendix C). The free molecule in the solution (1:1 ACN, H2O) decays with a single exponential
and a lifetime of about 45.67 ps. The encapsulated molecule shows double exponential decay with
a fast component of around 1.36 ps and a slow component at 8.91 ps. These two components could
be a result of several different phenomena. The hydrophobic (PCL) bilayer is the most likely area
for the dye to accumulate in the nanoparticle. As PCL is semicrystalline in nature
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, the

hydrophobic bilayer should have a semicrystalline arrangement; thus, the dye located in different
regions should have different aggregation natures. This may lead to a double exponential decay in
the excited state lifetime. When looking at the absorption spectra of the free and encapsulated dye,
it is evident that the encapsulated dye shows two absorption maxima (710 nm, 816 nm) while the
free dye shows only one (810 nm) (Fig. 97, Appendix C). The wavelength gap (106 nm) of the
shift for the new peak (710 nm) provides indirect evidence of an H-aggregated state of the dye.
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4.2.6 CELLULAR UPTAKE AND CYTOTOXICITY
In order to evaluate the potential of C5 loaded nanoparticles in biological imaging, C5 dye
fluorescence was measured after trafficking into HEK cells (Fig. 24a). Simultaneously,
LysoTracker (green) was used to track the distribution and accumulation of dye loaded
nanoparticles in the cellular organelles. When looking at the overlapped fluorescence images of
C5 and lysotracker, both signals are given from the same areas in the cytoplasm and no signal from
the nucleus(Fig. 24c). This suggests that the dye loaded nanoparticles traffic through endosomes
after uptaking into the cells and finally accumulate in the lysosomes.232 As the LDBC is made of
biodegradable materials, the polymeric nanocarrier is expected to degrade inside the lysosomes
after performing desired end task (imaging/therapy). However, the biological degradation
mechanisms of these polymeric systems have not yet been studied.

Figure 22. (a) HEK cells after exposure to dye-loaded nanoparticles (b) cytotoxicity (percentage)
was determined by the LDH assay (c) C5 dye fluorescence alone (red) in HEK cells (d)
LysoTracker fluorescence (green) (e) a merge of the bright field with LysoTracker and C5.
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The cytotoxicity of C5-loaded nanoparticles and the free nanoparticle (no loaded dye) was
tested with HEK cells. The observed cell viability for C5 loaded nanoparticles was ≥ 87.5 %, even
at the highest concentration tested (50 μg/mL). The free nanoparticles showed ≥ 97% cell viability
for all the concentrations (Fig. 24), which indicates both dye-loaded and free nanoparticles are
generally non-toxic to living human cells.
4.3 CONCLUSIONS AND FUTURE WORK
This work presents a successful attempt made to enhance the hydrophobic loading
efficiency and mechanical stability of LDBC nanoaggregates by introducing core-cross linking.
Noncovalent crosslinking was made via pi-pi stacking in the polyester bilayer of polymeric
vesicles. The ɛ-caprolactone monomer was modified via a phenyl substitution, and different weight
ratios (5% and 10% concerning the hydrophobic block) were introduced to the liner PCL chain of
the LDBC. In addition to the conventional structural characterization with NMR and GPC, TGA
provided qualitative evidence for the reliability of the synthetic strategy employed. In comparison
with an LDBC system with no phenyl substituents, a 37.1% decrease in the CAC was observed,
indicating the enhanced mechanical stability of core-crosslinked nanoparticles. Preliminary
encapsulation studies showed a 27.3 % - 41.2 % relative increase of hydrophobic loading
efficiency towards selected hydrophobic guest molecules. A near-infrared (NIR) emissive cyanine
dye C5 was successfully loaded into these LDBC nanocarriers, and the photothermal efficiency
was compared with ICG. C5 loaded nanocarriers showed photothermal efficiency of 49.4 %, which
is almost similar to the efficacy of ICG (47.2 %). Furthermore, they increased the temperature
from 21.6 ℃ to 66 ℃ after 20 minutes of photothermal activity. The results obtained so far
indicates that the pendant phenyl groups are introduced to the PCL chain of PCL-PAMAM
LDBCs. The nanoparticles formed by these systems demonstrated enhanced mechanical stability
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and hydrophobic loading efficiencies because of the pi-pi interactions induced by the pendant
phenyl groups.
Preliminary biological studies proved that the nanoparticles formed by PhPCL-G3 LDBCs
are nontoxic to living cells. As the next step of this work, extended biological studies are needed
to be carried out to evaluate the theranostic potential of these nanoparticles.

4.4 EXPERIMENTAL
4.4.1 MATERIALS AND METHODS
Common solvents, HPLC solvents, and reagents were purchased from commercial
suppliers (Sigma-Aldrich and Fisher Scientific) and used without additional purification.
PAMAM-G3-Boc, 70-CL-G3, and C5 were prepared as previously reported.187,192,232 Indocyanine
green (ICG) was purchased from Sigma-Aldrich. All synthetic procedures were carried out under
ultra-purified nitrogen conditions, and standard Schlenk line techniques were equipped unless
otherwise specified. Chloroform (99.9%,Acros), chlorobenzene (99.8%, Sigma-Aldrich), and εcaprolactone (99%, BTC) were distilled over CaH2. Tin(II) 2-ethylhexanoate (Sn(Oct)2,
92.5−100%, Sigma-Aldrich) was dried under vacuum (−100 kPa) for five days and stored in a
glovebox (O2 and H2O < 0.1 ppm). PAMAM-G3Boc [the macroinitiator used for ring-opening
polymerization (ROP)] and phenyl substituted Ɛ-caprolactone (Ph-εCL) were freeze-dried before
use. All the weighing for the ROP was done in a glovebox. 1H(13C) NMR spectra were collected
on a 300 or a 400 MHz spectrometer [Bruker Avance spectrometers (Bruker, Germany)]. Chemical
shifts (δ) are denoted in parts per million (ppm) relative to an internal standard (tetramethylsilaneTMS) and referenced to a protonated solvent obtained from Cambridge Isotope Laboratories, Inc.
(CDCl3: δH 7.26 ppm, δC 77.16 ppm; MeOD: δH 3.31, 4.87 ppm). Abbreviations used are s
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(singlet), d (doublet), t (triplet), q (quartet), m (multiplet), and b (broad). Gel permeation
chromatography (GPC) measurements were done using DMF, and measurements were done at a
flow rate of 0.8 mL/min at 55 ℃. A Shimadzu 20A GPC system equipped with two PSS SDV
analytical 1000 Å columns and a differential refractive index detector were used. The data was
evaluated using Astra 7.0 software. The GPC system was calibrated using Polymethylmethacrylate
(PMMA) standards. A JEOL 1230 TEM was used at 100 kV to obtain electron microscopy images
using a bottom-mounted charge-coupled device (CCD) camera (Gatan Orius 831). TEM sample
preparation and negative staining were done using a previously reported method.232 HEK293 cells
and Drosophila S2 were cultured according to a method followed in previous work.232

4.4.2 SYNTHESIS OF Ph-CL
Phenyl substituted -caprolactone was synthesized via Baeyer–Villiger oxidation of 4Phenylcyclohexanone.248 As outlined in Scheme 5, 4-Phenylcyclohexanone (200 mg, 1.15 mmol,
1.0 eq.) and benzoyl peroxide (741 mg, 2.30 mmol, 2.0 eq.) were dissolved in 5 mL of DCM. H2O2
(574 µL of a 60% solution in H2O, 5.74 mmol, 5.0 eq.) was then added, and the mixture was stirred
at room temperature for 16 h. After that, 100 mL of diethyl ether (Et2O) was added to the resulting
mixture and washed with sat.aq. Na2SO3 and sat.aq. NaHCO3 (aq) (two washing cycles with 25
mL of each sat.aq solution) and dried over anhydrous MgSO4. The resulting solution was
concentrated to 1 mL and directly loaded onto a silica column and eluted with 10:1 hexanes:
acetone mobile phase. Ph-εCL was obtained as white needle-like crystals (69.2% isolated yield).
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4.4.3 SYNTHESIS OF PhPCL-G3
Phenyl substitute PCL-PAMAM (PhPCL-G3) LDBCs were synthesized by modifying a
previously reported route.232 A Boc protected generation three (G3) PAMAM dendron (PAMAMG3Boc) was used to initiate the ROP of a mixture of -caprolactone and Ph-εCL by employing
Sn(Oct)2 as the catalyst (Scheme 4). Different wt% of Ph-εCL (5%, 10%, and 20% concerning
hydrophobic wt%) were introduced by varying the feed ratio for Ph-CL monomer while
maintaining the hydrophobic weight percent of the whole LDBC system constant (70%
hydrophobic wt%, Table 15). The percentage of Ph-CL was used to represent each system. For
example, 10-PhPCL-G3 stands for the LDBC system that takes 10% of the hydrophobic weight
by PhPCL. Trifluoroacetic acid (TFA) was used to remove the Boc protection of the terminal
amine on the PAMAM block and make the system amphiphilic. 192,232
4.4.4 CHARACTERIZATION OF BOC-PROTECTED INTERMEDIATES
The molar mass and the degree of polymerization (DP) was calculated using proton NMR
spectra for all the precursors (i.e., before the Boc deprotection). Either MeOD, or CDCl3 was used
as the solvent with TMS as the internal standard. GPC was utilized to confirm the molar masses
calculated by NMR and obtain the polydispersity index (PDI) of the polymers.

4.4.5 PREPARATION AND CHARACTERIZATION OF SELF-ASSEMBLED AGGREGATES
After the Boc deprotection, the resulting LDBCs were analyzed by thermogravimetric
analysis (TGA) and differential scanning calorimetry (DSC) to evaluate the thermal stability and
qualitative compositions. For TGA, a TA Instruments TGA 55 was employed. A platinum pan was
used for each sample, and the thermal studies were conducted under a nitrogen atmosphere within
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the temperature range of 25 to 500 °C at a ramp rate of 20 °C/min. For DSC, a TA Instruments
DSCQ1000-0620 v9.9 was used. DSC scans were done at ramp rates of 20 °C/min with three
heating/cooling cycles. The data were analyzed (for both TGA and DSC) using TA Instruments
Universal Analysis 2000 4.5A software.
5-PhPCL-G3 and 10-PhPCL-G3 LDBC systems were formed into nanoparticles via a
previously reported nanoprecipitation method.

192,232

1 mg of LDBC was dissolved in THF (200

µL), and the resulting solution was added dropwise (1 drop/sec) to a vial containing MilliQ water
(1 mL) while gently stirring and sonicating. THF was allowed to evaporate under constant airflow.
Nanoformulations were allowed to equilibrate for 12 h before testing.
Particle size and zeta potential (ζ-potential) measurements were carried out on a Zetasizer
Nano ZS (Malvern Instrument) using a He−Ne laser (633 nm) detector angle of 173° at 25 °C.
Concentration was kept 1 mg/mL for all the systems, and all measurements were done in triplicate
to assure consistency. Morphologies of the nanoparticles were obtained by environmental TEM
and cryo-TEM.
The pyrene fluorescence probe method was carried out to measure the CAC of the LDBC
nanoparticles. 25,20 The experiment was carried out with a series of eight concentrations (10−8 to
10−1 mg/L). The fluorescence spectra were taken on a Varian Cary fluorescence spectrometer
(Agilent Technologies).

4.4.6 ENCAPSULATION STUDIES
Curcumin, indolizine cyanine C5,187 and ICG were separately loaded into nanoparticles.
The encapsulation efficiency (EE%) and loading efficiency (DL%) were calculated for each dye
using Equations 4 and 5 (Chapter 3).
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APPENDIX A: SUPPLEMENTARY INFORMATION FOR CHAPTER 2
Reagents and solvents were purchased from commercial sources and used without further
purification unless otherwise specified. THF and DMF were degassed in 20 L drums and passed
through two sequential purification columns (activated alumina; molecular sieves for DMF) under
a positive argon atmosphere. All synthetic procedures were carried out under argon atmosphere
using standard schlenk line techniques unless otherwise stated. 1,8-Diazabicyclo[5.4.0]undec-7ene (DBU, 98%, Acros); Chloroform (99.9%, Acros); , were distilled over CaH2. All the Lactides
(L, DL) were recrystallized using toluene and dried under high vacuum (-100 kPa). Macro
initiators (PAMAM-G3-BOC) used for ring-opening polymerization (ROP) were freeze-dried
before use. All the weighing for the ROP was done in a glove box. 1𝐻 and 13𝐶 NMR were recorded
on Mercury 300 or INOVA 500 spectrometer. Chemical shifts (𝛿) are given in parts per million
(ppm) relative to TMS and referenced to residual protonated solvent purchased from Cambridge
Isotope Laboratories, Inc. (𝐶𝐷𝐶𝑙3: 𝛿H 7.26 ppm, 𝛿C 77.16 ppm; DMSO-d6: 𝛿H 2.50 ppm, 𝛿C
39.52 ppm, MeOD: 𝛿H 3.31, 4.87 ppm). Abbreviations used are s (singlet), d (doublet), t (triplet),
q (quartet), quin (quintet), hp (heptet), b (broad), and m (multiplet).Matrix-assisted laser desorption
time of flight mass spectrometry (MALDI-TOF MS) data was acquired using a Bruker-Daltonics
Autoflex III mass spectrometer with delayed extraction using the reflector and positive ion mode.
The samples were prepared by a combination of polymeranalyte (2 mg/mL) in THF, trans-2-[3(4-
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tert-butylphenyl)-2-methyl-2-propenylidene]malononitrile (DCTB) (20 mg/mL) in THF as the
matrix, and sodium trifluoracetic acid (2 mg/mL) in THF as the counter ion in a 15:15:1 ratio.
MALDI-TOF MS data were calibrated against SpheriCal dendritic calibrants from Polymer
Factory (Stockholm, Sweden). The samples were Mn and Mw for all polymers were calculated
using PolyToolssoftware.A JEOL 1230 TEM was operated at 100 kV to collect the transmission
electron microscopy images using a Gatan Orius 831 bottom mounted CCD camera. Sampl es
were made up 1 day in advance, then filtered and diluted within 1 hour of use. A second aliquot of
sample was set aside for 3 days before filtering, diluting and preparing in the same manner.
Formvar/carbon-coated, 300 mesh grids were plasma cleaned just prior to applying 15uL of sample
solution. The sample was allowed to settle for 10 minutes before wicking away with a small wedge
of filter paper. Negative staining was carried out immediately following by applying 7uL of 1%
uranyl formate to the grid and lightly wicking after 30 seconds. Prepared grids air-dried for no less
than 1 hour before TEM observation
SYNTHETIC DETAILS
PAMAM-G-0.5 (2)
To the stirred solution of ethanol amine (10.0 g, 0.16 mmol) in 50 mL of methanol, methyl
acrylate (MA) (70.75 g, 0.82 mmol) in 150 mL of methanol was added dropwise under salted ice.
After the completion of the addition of MA, the reaction mixture was allowed to come to room
temperature and then was subjected to heating at 35 ℃ overnight. Upon 1H NMR confirmation of
completion, MA was co-evaporated in-vacuo three times with butanol, three washes with reagent
alcohol, and three with MeOH until complete removal was confirmed by 1H NMR in CDCl3.1H
NMR (CDCl3, 500 MHz) δ 2.46- 2.51(2H, t), 2.59-2.63 (2H, t), 2.79-2.84 (4H, t), 3.56 – 3.60 (2H,
t), 3.68(6H, s); Solvent impurity: MeOH.
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PAMAM-G-1.0 (3)
To the stirred solution of ethylenediamine (EDA) (52.1 g, 0.866 mmol) in 100 mL of
methanol, PAMAM-G0.5 (10.17g, 0.043mmol) in 50 mL of methanol was added dropwise under
salted ice. After the completion of addition, the reaction mixture was allowed to come to room
temperature and then was subjected to heating at 35 ℃ for overnight. Upon 1H NMR confirmation
of completion, MA was co-evaporated in-vacuo three times each with butanol, reagent alcohol,
and MeOH until complete removal was confirmed by 1H NMR in MeOD.1H NMR (MeOD, 500
MHz) δ 2.34-2.38 (4H, t), 2.63 (2H, t), 2.68-2.72 (4H, t), 2.78-2.83(4H, t), 3.21-3.25 (4H, t), 3.45
(2H, s), 4.87. Solvent Impurities: n-BuOH δ 0.90-0.95(3H, t), 1.31-1.40 (2H, m), 1.43-1.54 (2H,
m).
PAMAM-G-1.5 (4)
To the stirred solution of MA (106.60 g, 1.24 mmol) in 200 mL of methanol, PAMAM-G1.0 (11.96
g, 0.124 mmol) in 50 mL in methanol was added dropwise under salted ice. After the completion
of addition, the reaction mixture was allowed to come to room temperature and then was subjected
to heating at 35 ℃ for two days. Upon 1H NMR confirmation of completion, MA was coevaporated in-vacuo three times with butanol, three with reagent alcohol, and three with MeOH
until complete removal was confirmed by 1H NMR in CDCl3. 1H NMR (CDCl3, 500 MHz) δ 2.382.40 (4H, t), 2.42-2.46 (8H, t), 2.53-2.57 (4H, t), 2.64-2.65 (2H, t), 2.73- 2.78 (8H, t), 2.81- 2.85
(4H, t), 3.27-3.29 (4H, t), 3.61, 3.63 (2H, t), 3.67 (12H, s); Solvent Impurities: MeOH.

PAMAM-G-2.0 (5)
To the stirred solution of EDA (47.56 g, 792.59 mmol) in 100 mL of methanol, PAMAM-G1.5
(12.51g, 19.73 mmol) in 60 mL in methanol was added dropwise under salted ice. After the
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completion of addition, the reaction mixture was allowed to come to room temperature and then it
was subjected to heating at 35 ℃ for three days. Upon 1H NMR confirmation of completion, MA
was co-evaporated in-vacuo three times with butanol, three with reagent alcohol, and three with
MeOH until complete removal was confirmed by 1H NMR in MeOD. 1H NMR (MeOD, 500 MHz)
δ 2.39-2.44 (12H, t), 2.60-2.65 (4H, t), 2.67-2.69 (2H, t), 2.75- 2.79 (8H, t), 2.81-2.85 (12H, t),
3.28-3.32 (12H, t), 3.35-3.36 (2H, t), 3.65-3.69 (2H, t); Solvent Impurities: MeOH, t-BuOH.

PAMAM-G-2.5 (6)
To the stirred solution of MA (71.84 g, 834.483 mmol) in 150 mL of methanol, PAMAM-G2.0
(12.45 g, 16.689 mmol) in 60 mL in methanol was added dropwise under salted ice. After the
completion of addition, the reaction mixture was allowed to come to room temperature and then it
was subjected to heating at 35 ℃ for four days. Upon 1H NMR confirmation of completion, MA
was co-evaporated in-vacuo three times with butanol, three with reagent alcohol, and three with
MeOH until complete removal was confirmed by 1H NMR in CDCl3. 1H NMR (CDCl3, 500 MHz)
δ 2.35-2.38 (12H, t), 2.42-2.45 (16H, t), 2.53-2.56 (8H, t), 2.57- 2.59 (4H, t), 2.60 (2H, t), 2.742.81 (28H, m), 3.26-3.29 (12H, t), 3.62-3.62 (2H, t), 3.67 (24H, s). Solvent Impurities: IPA;
MeOH.

PAMAM-G-3.0 (7)
To the stirred solution of EDA (34.31 g, 570.99 mmol) in 70 mL of methanol, PAMAM-G2.5
(10.24 g, 7.137 mmol) in 50 mL in methanol was added dropwise under salted ice. After the
completion of addition, the reaction mixture was allowed to come to room temperature and then it
was subjected to heating at 35 ℃ for four days. Upon 1H NMR confirmation of completion, MA
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was co-evaporated in-vacuo three times with butanol, three with reagent alcohol, and three with
MeOH until complete removal was confirmed by 1H NMR in MeOD. 1H NMR (MeOD, 500 MHz)
δ δ 2.38-2.42 (28H, t), 2.59-2.61 (12H, t), 2.73-2.77 (16H, t), 2.81-2.84 (28H, t), 3.26-3.30 (28H,
t), 3.64-3.67 (2H, t). Solvent Impurities: n-BuOH, MeOH and tBuOH

PAMAM-G-3-BOC (8)
To the stirred solution of PAMAM-G3.0 (15.06 g, 9.041 mmol) in 150 mL of methanol, ditertbutyl dicarbonate (Boc Anhydride) (39.85 g, 0.182 mmol) in 120 mL in methanol was added
dropwise under salted ice. After complete addition of Boc Anhydride, the reaction was allowed to
warm to room temperature. The reaction continued at room temperature for two days. Upon 1H
NMR confirmation of completion, a single rotovap ensued. The PAMAM product was dissolved
into a minimal amount of DCM which was followed by precipitation via separatory funnel into 5x
mL of stirring, pure hexane. After settling, the hexane layer was decanted, and the remaining
product was air-dried. This precipitation, decanting, and air-drying process was repeated twice
more. A final 1H NMR ensured the removal of Boc Anhydride. 1H NMR (CDCl3, 500 MHz) δ
1.44 (72H, s), 2.37 (28H, t), 2.55 (14H, t), 2.75 (28H, t), 3.26 (28H, t), 3.34 (20H, t), 3.64 (2H, t);
Solvent Impurities: DCM.

(90/70/50/30) – (DL/L) – G3 – BOC (9)
To a stirred solution of PAMAM – G3 – BOC (5) (1 g, 0.4 mmol) and L or DL-lactide (1.5 g,
10.98 mmol) in chloroform (12.5 ml), DBU (76 µL, 1 mmol) was added under inert atmosphere
and then stirred for 4 h. Benzoic acid (186 mg, 1.5 mmol) was added to the reaction mixture stirred
for another 30 minutes. The final reaction mixture was added dropwise to 250 ml of a solvent
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mixture: containing diethylether:hexane:MeOH (15:5:1) and stirred for 30 min. Stirring was
stopped and the reaction mixture was allowed to settle down. The resulting white precipitate was
filtered out, dissolved in chloroform (5 ml), and the precipitation procedure was repeated three
times to get pure product. The resulting white powder was dried under high vacuum at 45 ℃ for
24 hours to obtain the pure product with 91% yield (2.2 g). 1H NMR (CDCl3, 500 MHz) δ 1.42
(72H, s), 1.56 (174H, m), 2.36 (28H, b), 2.53 (14H, b), 2.73 (28H, b), 3.23 (28, b), 3.32 (18, b),
3.46 (2, t), 5.18 (58, m). (All amounts and NMR chemical shifts are given for the 70-(DL/L)-G3BOC. For the 90, 50 and 30 systems, procedure is the same but amounts of the materials are varied
according the weight ratio calculations. Analysed NMR spectra for all the systems are given in the
NMR spectra section).

Table 6. Screening of organic catalyst
Catalyst

% equivalents

Monomer

Reaction time/
hours

% monomer
conversion

DMAP

40%

L-Lactide

6

0%

40%

L-Lactide

12

70%

95%

L-Lactide

12

91%

TBD

10%

L-Lactide

12

18%

DBU

20%

L-Lactide

4

100%
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NMR SPECTRA

Figure 23. 1H NMR for PAMAM-G-0.5 (2) (CDCl3, 300 MHz)

Figure 24. 1H NMR for PAMAM-G-1.0 (3) (MeOD, 300 MHz)
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Figure 25. 1H NMR for PAMAM-G-1.5 (4) (CDCl3, 300 MHz)

Figure 26. 1H NMR for PAMAM-G-2.0 (5) (MeOD, 300 MHz)
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Figure 27. 1H NMR for PAMAM-G-2.5 (6) (CDCl3, 500 MHz)

Figure 28. 1H NMR for PAMAM-G-3.0 (7) (MeOD, 300 MHz)
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Figure 29. 1H NMR for PAMAM-G-3.0-BOC (8) (CDCl3, 500 MHz)

Figure 30. 1H NMR for 90-DL-G3-Boc (CDCl3, 500 MHz)
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Figure 31. 1H NMR for 70-DL-G3-Boc (CDCl3, 500 MHz)

Figure 32. 1H NMR for 50-DL-G3-Boc (CDCl3, 500 MHz)
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Figure 33. 1H NMR for 30-DL-G3-Boc (CDCl3, 500 MHz)

MALDI-TOF MS

Figure 34. MALDI-TOF mass spectrum for PAMAM-G3-Boc macroinitiator
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Figure 35. MALDI-TOF mass spectrum for PAMAM-G3-Boc macroinitiator after the reaction
with acetic anhydride
Table 7. Molecular weight and nomenclature
MW
protected
macroinitiator
90-L/DL-G3
70-L/DL-G3
50-L/DL-G3
30-L/DL-G3

/ g mol
2460
2460
2460
2460

-1

MW
deprotected
macroinitiator/
-1

g mol
1667
1667
1667
1667

MW
Lactide
Block/
-1

g mol
15 003
3890
1667
714

MW
protected
LDBC/
-1

g mol
17 463
6350
4127
3174

MW
deprotected
LDBC/
-1

g mol
16 670
5557
3334
2381

Molecular weight (MW) of the lactide chain has been calculated using the MW of the deprotected
macroinitiator because our desired end product is amphiphilic LDBC. We have done the GPC
using the protected samples in order to overcome the solubility issues. There the MW of the
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protected systems are used in the GPC data table and the nomenclature comes from the deprotected
version.
GPC CHROMATOGRAMS
Table 8. Molecular weight characterization of LDBCs by NMR, GPC (in DMF) and GPC (in THF)
NMR

Sample

Yields MwNMR

GPCDMF
Mth/
mol

-1

GPCTHF

g Mn
mol

/g Mw/g
-1

mol

-1

PDI

Mn
mol

/g Mw/g
-1

mol

-1

PDI

90-L-G3BOC

94%

20,028

17,465

12,084

20,659

1.71

13,259

19,043

1.44

70-L-G3BOC

91%

6564

6350

8,189

12,012

1.52

7,470

10,988

1.47

50-L-G3BOC

86%

3902

4127

5,205

6,565

1.28

2,360

3,681

1.55

30-L-G3BOC

84%

2892

3175

3,862

4,248

1.10

1,823

2,088

1.45

90-DLG3-BOC

92%

20,964

17,465

15,303

24,203

1.58

18,053

22,756

1.47

70-DLG3-BOC

87%

6852

6350

8,255

11,688

1.47

7,198

10,415

1.44

50-DLG3-BOC

87%

4044

4127

5,540

6,972

1.28

2,430

3,904

1.60

30-DLG3-BOC

83%

2964

3175

4,402

4,941

1.13

1,912

2,207

1.15
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Figure 36. GPC chromatograms for LDBC series of L-Lactide with PAMAM-G3, Boc protected;
mobile phase as dimethylformamide (DMF); 90-L-G3Boc (red), 70-L-G3Boc (blue), 50-L-G3Boc
(green), 30-L-G3Boc (yellow), PAMAM-G3Boc (black)

Figure 37. GPC chromatograms for LDBC series of DL-Lactide with PAMAM-G3, Boc
protected; mobile phase as dimethylformamide (DMF); 90-DL-G3Boc (red), 70-DL-G3Boc
(blue), 50-DL-G3Boc (green), 30-DL-G3Boc (yellow), PAMAM-G3Boc (black)
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Figure 38. GPC chromatograms for LDBC series of L-Lactide with PAMAM-G3 Boc protected;
mobile phase as tetrahydrofuran (THF); 90-L-G3-BOC (red), 70-L-G3-BOC (blue), 50-L-G3BOC (green), 30-L-G3-BOC (yellow), PAMAM-G3-BOC (black).

Figure 39. GPC chromatograms for LDBC series of DL-Lactide with PAMAM-G3 Boc protected;
mobile phase as tetrahydrofuran (THF); 90-DL-G3-BOC (red), 70-DL-G3-BOC (blue), 50-DLG3- BOC (green), 30-DL-G3-BOC (yellow), PAMAM-G3-BOC (black).
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THERMAL ANALYSIS DATA

Figure 40. TGA of LDBCs.

Table 9. TGA and DSC results for LDBCs.
LDBC

Tg/(oC)DSC

TGA

G3-PAMAM-Boc

51.81

G3-PAMAM

41.32

90-L-G3

208.80

57.66

70-L-G3

173.28

41.24, 53.66

50-L-G3

136.54

39.58

30-L-G3

182.91

39.37

90-DL-G3

194.19

52.25

70-DL-G3

193.52

39.42, 50.42

50-DL-G3

185.02

36.1, 46.7

30-DL-G3

167.27

32.6
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DLS SPECTRA

Figure 41. DLS spectra for 70-L-G3-BOC direct dissolution; left: Size distribution by intensity,
right: Size distribution by volume.

Figure 42. DLS spectra for 50-L-G3-BOC direct dissolution; left: Size distribution by intensity,
right: Size distribution by volume.
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Figure 43. DLS spectra for 30-L-G3-BOC direct dissolution; left: Size distribution by intensity,
right: Size distribution by volume.

Figure 44. DLS spectra for 70-DL-G3-BOC direct dissolution; left: Size distribution by intensity,
right: Size distribution by volume.
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Figure 45. DLS spectra for 50-DL-G3-BOC direct dissolution; left: Size distribution by intensity,
right: Size distribution by volume.

Figure 46. DLS spectra for 30-DL-G3-BOC direct dissolution; left: Size distribution by intensity,
right: Size distribution by volume; horizontal axis: Diameter (nm).
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SURFACE CHARGE ANALYSIS
Table 10. DLS and Zeta potential results for LDBCs.
Sample

Size (nm) Size (nm)
Diameter
Diameter
(TEM)
(DLS)

PDI

ζ-potential
(mV)

Morphology

B: 70-L

20.8

122.4

0.180

36.8±1.48

Mixture (worms
and vesicles)

C: 50-L

12.2

24.2

0.463

48.2±2.08

Bilayered vesicles

D: 30-L

14.2

15.6

0.467

24.7±2.71

Core shell micelle

F: 70-DL

19.2

21.0

0.212

27.0±2.99

Bilayered vesicles

G: 50-DL

12.06

18.0

0.328

41.9±2.29

Bilayered vesicles

H: 30-DL

10.6

18.0

0.570

35.6±3.81

Core shell micelle

(DLS)

TEM IMAGES

Figure 47. 70-L-G3-NH3; Nanoparticles formed in water by direct dissolution after 12h.
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Figure 48. 50-L-G3-NH3; Nanoparticles formed in water by direct dissolution after 12h.

Figure 49. 30-L-G3-NH3; Nanoparticles formed in water by direct dissolution after 12h.
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Figure 50. 70-DL-G3-NH3; Nanoparticles formed in water by direct dissolution after 12h.

Figure 51. 50-DL-G3-NH3; Nanoparticles formed in water by direct dissolution after 12h.
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Figure 52. 30-DL-G3-NH3; Nanoparticles formed in water by direct dissolution after 12h.

Figure 53. Enlarged TEM images of 70-L-G3-NH3 (left) and 70-DL-G3-NH3 (right);
Nanoparticles formed in water by direct dissolution after 12h.
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Table 11. Morphologies observed via TEM.

w/w%
hydrophobic liner
polylactide

Morphology of the nano aggregate

DL-Lactide

L-Lactide

70

core-shell vesicle

core-shell vesicle,
worms (elongated
micells)

50

core-shell vesicle

core-shell vesicle

30

core-shell vesicle

core-shell micelle

90a

core-shell vesicle

worms, dumbbells and
core-shell vesicle

All the observed morphologies via TEM. The cystamine stereotype (L-lactide) showed majority
of elongated micelles (worm-like aggregates) with the increase of hydrophobic weight ratio to
70%. The given morphologies in Table 3 of the main text were deduced by the best curve fit with
the SAXS data and some of the TEM images provide evidence for the presence of bilayered
vesicles. a Nanoparticles from 90% polyester LDBCs were prepared via nanoprecipitation.
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CAC DATA
Table 12. CAC data for LDBC series.
LDBCs

CAC (mg/L)

70-L-G3

1.82  0.49

50-L-G3

6.59  1.14

30-L-G3

9.75  3.07

70-DL-G3

0.91  0.23

50-DL-G3

1.41  0.30

30-DL-G3

9.31  3.57

Figure 54. Excitation ratio vs. log concentration for 70-L-G3 (left) and 50-L-G3(right).
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Figure 55. Excitation ratio vs. log concentration for 30-L-G3 (left) and 70-DL-G3(right).

Figure 56. Excitation ratio vs. log concentration for 50-DL-G3 (left) and 30-DL-G3(right).
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APPENDIX B: SUPPLEMENTARY INFORMATION FOR CHAPTER 3
SYNTHESIS
(90/70/50)-PCL–G3Boc
A solution of PAMAM–G3–Boc (1) (1.0 g, 0.40 mmol) and ε-caprolactone (1.58 g, 13.84
mmol) in a mixture of chlorobenzene (12.5 ml) and chloroform (0.5 ml) was heated to 90 °C as
the chloroform was evaporated and allowed to went through a bubbler. Tin(II) 2-ethylhexanoate
(Sn(Oct)2) (98.82 mg, 0.24 mmol) was added under an inert atmosphere, the mixture was heated
to 130 ℃, and then stirred for 10 h. The reaction mixture was cooled down to room temperature,
added dropwise into 250 ml of diethyl ether (Et2O) while stirring. A precipitate was formed
instantly. The mixture was kept stirring for 30 more minutes, and stirring was stopped. The
precipitate was allowed to settle, and Et2O was decanted from the mixture. Resulting light-yellow
solid was redissolved in chloroform (5 ml) and added dropwise into 250 ml of Et2O, as mentioned
in the previous step. The precipitation procedure was repeated three times to get a pure product.
The resulting light-yellow solid was dried under a high vacuum at 45℃ for 24 hours to obtain the
pure product with a 86 % yield (2.21 g). 1H NMR (CDCl3, 500 MHz) 4.06 (t, J = 6.7 Hz, 68H),
3.46 (t, J = xx Hz, 2H), 3.32 (b, 18H), 3.23 (b, 28H), 2.73 (b, 28H), 2.53 (b, 14H), 2.36 (b, 28H),
2.31 (t, J = 7.5 Hz, 68H), 1.56 (m, 174H), δ 1.42 (s, 72H),
(All amounts and NMR chemical shifts are given for the 70-PCL-G3Boc. For the 90 and
50 systems, the procedure is the same, but amounts of the materials are varied according to the
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weight ratio calculations. Analyzed NMR spectra for all the systems that are given in the NMR
spectra section. Yields for 90 and 50-PCL-G3Boc are 88 % and 81%, respectively).
(90/70/50)–PCL–G3 NH3+ TFA–
To a stirred solution of (2) (1.0 g, 0.15 mmol) in chloroform (15 mL), trifluoroacetic acid
(TFA) (1.5 mL, 10% v/v) was added and stirred for 30 minutes. The final reaction mixture was
air-dried to remove the TFA. The resulting solid was dissolved in 5 mL of chloroform added
dropwise to 250 ml of diethyl ether while stirring. A precipitate was formed instantly. The mixture
was kept stirring for 30 more minutes, and the stirring was stopped. The precipitate was allowed
to settle, and Et2O was decanted from the mixture. The resulting light-yellow solid was redissolved
in chloroform (5 ml) and added dropwise into 250 ml of Et2O, as mentioned in the previous step.
The precipitation procedure was repeated three times to get a pure product. The resulting lightyellow solid was dried under a high vacuum at 30 ℃ for 24 hours to obtain the pure product with
a 91% yield (0.91 g). 1H NMR (300 MHz, CDCl3) δ 4.08 (t, J = 6.6 Hz, 61H), 2.33 (t, J = 7.4 Hz,
59H), 1.74 – 1.35 (m, 193H).
(All the amounts and NMR chemical shifts are given for the 70-PCL-G3Boc. For the 90
and 50 systems, the procedure is the same, but amounts of the materials are varied according to
the solvent amounts which are needed to dissolve each system.)
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NMR SPECTRA

Figure 57. 1H NMR for PAMAM-G3-Boc (1) (CDCl3, 500 MHz).

Figure 58. 1H NMR for 90-PCL-G3Boc (CDCl3, 300 MHz).
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Figure 59. 1H NMR for 70-PCL-G3Boc (CDCl3, 300 MHz).

Figure 60. 1H NMR for 50-PCL-G3Boc (CDCl3, 300 MHz).
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POLYMERIZATION KINETIC STUDIES

Figure 61. The percent conversion of the caprolactone monomer with 5% Sn(Oct)2 to produce a
block copolymer contains 70% PCL (wt%) initiated with Bnz-OH (left), PEG (right) as the
initiator.

Figure 62. The percent conversion of the caprolactone monomer with 10% (left) and 15% (right)
Sn(Oct)2 to produce a block copolymer containing 70% PCL (wt%) with PAMAM-G3-Boc as the
initiator.
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Figure 63. The percent conversion of the caprolactone monomer with 10% (left) and 20% (right)
Sn(Oct)2 to produce a block copolymer contains 30% PCL (wt%) with PAMAM-G3-Boc as the
initiator.
According to the polymerization kinetic studies, small molecule initiators (benzyl alcohol,
BnzOH) drives the monomer conversion >90% with a 5% catalyst concentration. At the same
catalyst concentration, a macroinitiator (PEG) which does not have groups that can act as ligands
(such as amines) showed 85% monomer conversion in 8h. Nonetheless, with the PAMAM-G3Boc, no conversion was seen after 8h at 5% catalyst concentration. We believe the observed
deactivation of the catalyst is due to the branched and bulky architecture of the PAMAM dendron.
To achieve >90% conversion in 8h and synthesize a LDBC with 70% PCL (wt%), a 15% catalyst
concentration was required. LDBCs with higher PAMAM wt% required even higher catalyst
loading (i.e., 20% catalyst concentration for 30-PCL-G3), which is hypothesized to be due to the
metal-ligand interactions between the Sn metal center of the catalyst and the amine groups in
PAMAM.
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GPC CHROMATOGRAMS
The molar mass and DP of the Boc protected intermediates were calculated using 1H NMR
spectroscopy. The degree of polymerization (DP) of PCL was calculated by the integration values
of the peaks corresponding to methylene protons of the PCL chains and protons of the
characteristic PAMAM peaks using 1H NMR.

Figure 64. GPC chromatograms for the LDBC series of PCL with PAMAM-G3-Boc . The mobile
phase is N,N-dimethylformamide (DMF). 90-PCL-G3Boc (red), 70-PCL-G3Boc (green), 50-PCLG3Boc (yellow) and the macroinitiator (PAMAM-G3Boc, black).
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THERMAL ANALYSIS

Figure 65. TGA for 90-PCL-G3.

Figure 66. TGA for 50-PCL-G3.
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Figure 67. DSC thermogram for 90-PCL-G3.

Figure 68. DSC thermogram for 70-PCL-G3.
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Figure 69. DSC thermogram for 50-PCL-G3.

TEM IMAGES

Figure 70. Room temperature TEM images of (a) 90-PCL-G3 and (b) 70-PCL-G3. Nanoparticles
were formed in water by nanoprecipitation after 12h. Visualization was done with room
temperature TEM with uranyl formate as the contrasting agent.
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Figure 71. Nanoparticle clusters (secondary aggregates) observed in (a) 70-PCL-G3 and (b) 50PCL-G3 formulations, (c) An additional TEM image of 70-PCL-G3 that visualizes both individual
nanoaggregates and the clusters.
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Cryo TEM images did not give the desired resolution to visualize the bilayer vesicle or micellular
morphology. So, environmental TEM was carried out with a contrasting agent (uranyl formate). A
darker region in the spherical shaped particles is observed, which is believed to be the PCL bilayer.
The grids were not allowed to dry completely, and images were taken as soon as possible after the
grid was loaded to the TEM. This procedure was followed to prevent the complete evaporation of
water from the grid. As PCL has a Tg of -60 ℃, there is a possibility of distortion or flip of the
nanoparticle if the grid completely dries out. Therefore, morphological evidence obtained from
environmental TEM was only used as qualitative data. However, encapsulation studies provided
better evidence that 90-PCL-G3 and 70-PCL-G3 systems from bilayer vesicles (discussed in the
main text).
DLS
Table 13. DLS measured sizes of the nanoaggregates formed in water by LDBCs. Davg is the
average diameter calculated from TEM images, Dint is the intensity average diameter, DZ-avg is the
Z average diameter, and PDI is the polydispersity index.
System

DLS
Davg(TEM) /nm

Dint/nm

DZ-avg/nm

PDI

ζ potential
/mV

90-CL-G3

71.1

96.4

77.8

0.16

37.0

70-CL-G3

48.1, 29.8

51.6, 359.4

45.6

0.50

50.1

50-CL-G3

14.0

221.4, 16.7

110.2

0.53

72.4
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Figure 72. DLS intensity average size distribution of nanoaggregates formed in water by
nanoprecipitation.

Figure 73. DLS intensity average size distribution of nanoaggregates formed in water after
encapsulation of curcumin. (Dotted lines represent curcumin loaded nanoparticles, and the solid
lines represent empty nanoparticles).
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Figure 74. Volume and number average DLS size distributions for 70-PCL-G3

Figure 75. Zeta potential distribution for 90-PCL-G3.
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Figure 76. Zeta potential distribution for 70-PCL-G3.

Figure 77. Zeta potential distribution for 50-PCL-G3.
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CAC PLOTS

Figure 78. CAC plots for LDBCs and the values calculated by the pyrene fluorescence probe
method.
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ENCAPSULATION STUDIES
Table 14. Loading and encapsulation efficiencies of the nanoaggregates with curcumin and RhB.

90-CL-G3
70-CL-G3
50-CL-G3

DL%
21.7
13.7
0.61

Curcumin
EE%
Dh/nm
46.8
255.5
24.4
54.4
0.90
15.03

RhB
PDI
0.14
0.38
0.36

DL%
61.3
62.0
55.2

EE%
35.3
36.3
26.4

Dh/nm
88.8
89.2
21.5

PDI
0.17
0.59
0.31

Figure 79. (a)Vis-NIR absorption spectral for C3 in MeCN:H2O (1:1) (blue) and encapsulated in
90-PCL-G3 (yellow) in water , (b), (c) and (d) structures of C3, RhB, and curcumin respectively.
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OPTICAL ACTIVITY OF C3 ENCAPSULATED NANOPARTICLES

Figure 80. TAS plots and the curve fitting for the lifetime of the C3 loaded in 70-PCL-G3 (black
signal) and free C3. The pump is at 695 nm and probe at 480 nm.
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APPENDIX C: SUPPLEMENTARY INFORMATION FOR CHAPTER 4
SYNTHESIS
70-PCL-G3

Figure 81. Structure of 70-PCL-G3 LDBC, consists of 70 wt% hydrophobic (PCL) and 30 wt%
hydrophilic (PAMAM).
The synthesis of 70-PCL-G3 is reported in Chapter 3.
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Ph-εCL
Scheme 4. Synthesis of Ph-CL

The synthesis was done according to the procedure described in the general synthesis
section in Chapter 4. 1H NMR (400 MHz, Chloroform-d) δ 7.37 – 7.15 (m, 5H), 4.44 – 4.26 (m,
2H), 2.91 – 2.70 (m, 3H), 2.20 – 1.77 (m, 4H).
(5/10/20)-PhPCL-G3
A mixture of PAMAM–G3–Boc (1) (1.0 g, 0.40 mmol), PhPCL (160 mg, 0.84 mmol) and
ε-caprolactone (1.42 g, 12.5 mmol) in a mixture of chlorobenzene (15 ml) was heated to 90 °C.
Tin(II) 2-ethylhexanoate ( Sn(Oct)2) (98.82 mg, 0.24 mmol) was then added under an ultra-high
pure nitrogen environment, and the mixture was heated to 130 ℃. The mixture was stirred at 130
℃ for 10 h. The reaction mixture was allowed to cool down to room temperature, added dropwise
into 250 ml of diethyl ether (Et2O) while stirring. A precipitate was formed and stuck on the wall
of the flask. The mixture was kept stirring until a clear solution is observed, and stirring was
stopped. Then Et2O was decanted from the mixture. The resulting yellow solid was redissolved in
chloroform (5 ml) and added dropwise into 250 ml of Et2O, similar to the previous step. The
precipitation steps were repeated three times to get a pure product. The resulting yellow solid was
dried under a high vacuum at room temperature for 24 hours to obtain the pure and dried product
with an 83 % yield (2.03 g).
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Table 15. wt % of each block concerning the LDBC and wt% of each PCL type (i.e., PhPCL or
PCL) concerning the hydrophobic block.
wt% of the
hydrophilic block
(PAMAM-G3)
5-PhPCL-G3

30

wt% of the
hydrophobic
block (PCL +
PhPCL)
70

10-PhPCL-G3

30

20-PhPCL-G3

30

PCL and PhPCL wt% concerning
hydrophobic block weight
PhPCL wt%
PCL wt%
5

95

70

10

90

70

20

80

NMR SPECTRA

Figure 82. 1H NMR for Ph-εCL (400 MHz, Chloroform-d) δ 7.37 – 7.15 (m, 5H), 4.44 – 4.26 (m,
2H), 2.91 – 2.70 (m, 3H), 2.20 – 1.77 (m, 4H).
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Figure 83. 1H NMR overlay of the (a) macroinitiator (PAMAM-G3-Boc), (b) LDBC intermediate
(10-PhPCL-G3Boc), and (c) LDBC after Boc deprotection (10-PhPCL-G3) in CDCl3.

GPC ANALYSIS
Table 16. Molecular weight analysis of LDBCs by NMR spectroscopy and GPC.
Mth
5-PhPCLG3Boc
10-PhPCLG3Boc

DP

nPhPCL

th

th

6350

34

1

6350

34

2

MNMR

DP

nPhPCL

NMR

NMR

Mn

Mw

PDI

1

%Ph
PCL
5.4

6247

33

6143

7676

1.25

6386

34

2

9.6

5280

6929

1.31

The notation of PhPCL-G3 denotes the LDBC composition, where phenyl substituted PCL
connected to a G3 PAMAM with a weight percentage is in respect to the caprolactone monomer
used; Mth, theoretical molar mass; DPth, theoretical degree of polymerization; Mn, number average
molar mass; Mw, weight-average molar mass; and PDI, polydispersity index.
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Figure 84. GPC chromatograms of PhPCL-G3Boc LDBC precursors.

THERMAL ANALYSIS
Table 17. Thermal Analysis Data (TGA) Confirming the Weight Ratios for Each LDBC.
System
PAMAM

10-PhPCLG3
5-PhPCLG3

30
30

Composition
PCL +
Ph
PhPCL
substituents
(wrt total
molar mass)
70
7
70

3.5
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1st step
Td
ΔW
(°C) (wt%)

2nd step
Td
ΔW
(°C)
(wt%)

3rd step
Td
ΔW
(°C)
(wt%)

226

32.5

321

67.5

422

8

220

33

314

67

410

NA

Figure 85. TGA of 10-PhPCL-G3

Figure 86. TGA of 5-PhPCL-G3.
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Figure 87. TGA and derived TG analysis of 5-PhPCL-G3.

Figure 88. DSC thermogram for 5-PhPCL-G3
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Figure 89. DSC thermogram for 10-PhPCL-G3.

ENCAPSULATION STUDIES
Table 18. DL % comparison between phenyl substituted and non-substituted LDBCs.

70-PCL-G3
5-PhPCL-G3
10-PhPCL-G3

Curcumin
13.70
13.73
17.50

Encapsulation efficiency (DL %)
C3
1.70
1.94
2.40
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C5
2.58
2.88
3.41

CRITICAL AGGREGATION CONCENTRATION (CAC)

Figure 90. CAC plots.
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DYNAMIC LIGHT SCATTERING (DLS)

Figure 91. Intensity average DLS comparison between phenyl substituted and non-substituted
LDBC nanoparticles.

Figure 92. Intensity average size distributions for 10-PhPCL-G3.
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Figure 93. Number average size distributions for 10-PhPCL-G3.

Figure 94. Volume average size distributions for 10-PhPCL-G3.
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Figure 95. Absorption spectra for free C5 in the solution and encapsulated in 10-PhPCL-G3
nanoparticles.

Figure 96. Emission spectra for free C5 in the solutionand encapsulated in 10-PhPCL-G3
nanoparticles.
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Figure 97. Excite state lifetimes for free C5 in the solution and encapsulated in 10-PhPCL-G3
nanoparticles.
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Extension Consortium Annual Meeting, Hattiesburg, MS, November 13, 2017.
Dal Williams, J. S.; Chandrasiri, I.; Watkins, D. L. “Janus-Type Linear-Dendritic Hybrids for
Targeted Drug Delivery,” (poster presentation), Applied Polymer Technology Extension
Consortium Annual Meeting, Baton Rouge, LA, November 7, 2016.

TEACHING AND MENTORING EXPERIENCE
University of Mississippi
Mentor, Watkins Research Group, Aug 2016 to present
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Mentored graduate researchers (Yaddehige, M. L, Derbigny, B.) on design, synthesis, and
characterization of polymers
Mentored graduate and undergraduate researches (Yaddehige, M. L, Derbigny, B., Parker, A.C.,
Barker, A., Weather, A.) on analytical instrumentation (NMR. GPC, UV-vis/NPR, fluorescence
spectroscopy, IR spectroscopy, MALDI-TOF mass spectroscopy, DLS)
Mentored graduate and undergraduate researches on lab safety and working ethics
Teaching Assistant, Dpt. of Chemistry and Biochemistry, Aug 2016 to Aug 2018
Mentored (organic chemistry) 46 college sophomores and juniors per semester
Supervised teaching experiments in organic and general chemistry laboratories, maintaining a safe
learning environment
MAS Holdings, Sri Lanka
Executive Team Leader, Product Development, Jul 2014 to Jul 2016
Piloted the development team of 54 individuals, including executives, team leaders, and team
members
Coached teams to use effective management and production tools including Lean Manufacturing,
Toyota Production System, and PDCA management
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HONORS AND AWARDS
Outstanding Organic Graduate Student, 2017
Awarded by American Chemical Society and the Department of Chemistry and Biochemistry,
University of Mississippi
Awarded to the graduate student with the best research and academic performance
National School on Neutron and X-Ray Scattering, 2018
Special educational and training program awarded by Argonne and Oak Ridge national
laboratories
University of Peradeniya, 2013
Special Honors Degree Program in Chemistry
Awarded to the undergraduate students with the highest GPA in chemistry
Golden Key International Honor Society, 2017
Membership is awarded to the students with the highest academic performance

ACTIVITIES AND MEMBERSHIPS
University of Mississippi, Oxford, MS
Sri Lankan Students Association, Founder and President, Apr 2019 to Apr 2020
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Green Grove Program, Volunteering, Dec 2019
Ole Miss Cricket Club, Member, University of Mississippi, Aug 2018 to 2020

PROFESSIONAL TRAINING
USM Xray Scattering Workshop, University of Southern Mississippi, Jul 9 to 10, 2020
National School on Neutron and X-Ray Scattering, Argonne and Oak Ridge
Laboratories, Jul 22 to Aug 4, 2018
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National

